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Abstract

TOWARDS UNDERSTANDING THE MECHANISM OF ACTION OF ABUSED
CATHINONES

By Rakesh Harsukhlal Vekariya, M. S.

A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science
at Virginia Commonwealth University.

Virginia Commonwealth University, 2012.

Major Director: Dr. Richard A. Glennon
Professor and Chairman, Department of Medicinal Chemistry

The dopamine transporter (DAT) mediates reuptake of dopamine from the synaptic cleft
into the presynaptic terminus and plays a critical role in maintaining the normal function of
dopaminergic neurons. DAT is the major target of widely abused psychostimulant drugs,
including cocaine and amphetamine. DAT also figures into disease states, and it is a target for
therapeutic drugs. It is known that cathinone and methcathinone, β-keto analogs of amphetamine
and methamphetamine, respectively, produce pharmacological actions similar to amphetamine.
Cathinone and methcathinone analogs are recently gaining in popularity on the
clandestine market (e.g. ‘bath salts’). Cathinone and methcathinone analogs as well as their

xiii
amphetamine and methamphetamine counterparts were synthesized and examined at the hDAT
expressed in Xenopus oocytes. One of the two major constituents of ‘bath salts’ (i.e.,
mephedrone) produced an electrophysiological signature similar to the dopamine releasing agent
S(+)-amphetamine

while

the

other

major

constituent

(i.e.,

MDPV)

electrophysiological signature similar to the dopamine re-uptake inhibitor cocaine.

produced

an

I. Introduction

Khat (Catha edulis, Celestraceae) is a plant, indigenous to the Arabian Peninsula and
tropical East Africa. The fresh leaves of the khat plant have been brewed as a ‘tea’ or chewed for
their central stimulant properties in the Arabian Peninsula and in certain regions of eastern
Africa. Cathinone was determined to be an active constituent of khat. Racemic cathinone and its
individual optical isomers were found to have pharmacological actions similar to amphetamine.
Methcathinone, the N-methyl analog of cathinone, was investigated by Glennon and co-workers.
It was found that cathinone and methcathinone produced discriminative stimulus effects similar
to S(+)-amphetamine in rats. The studies also showed that amphetamine, methamphetamine,
cathinone and methcathinone produced similar locomotor stimulation in mice.
There are number of new synthetic analogs of cathinone and methcathinone gaining in
popularity on the clandestine market and have created considerable attention. Although,
cathinone and methcathinone are controlled substances, most of their analogs are not. One of the
more popular synthetic cathinones is a combination known as ‘bath salts’ which contains
mephedrone and methylenedioxypyrovalerone. The major constituents of ‘bath salts’ were
recently scheduled (Schedule I). However, very limited data are available regarding the
pharmacology and mechanism of action of cathinone and methcathinone analogs. Therefore,
there is need for investigation in this area

1

Dopamine (DA) is involved in the control of numerous functions including locomotor
activity, reward mechanisms, cognition and neuroendocrine functions. In addition, the
dysfunction of DA system in CNS is related to a broad spectrum of neuropsychiatric disorders,
such as Parkinson’s disease, schizophrenia, Tourette’s syndrome, attention-deficit hyperactivity
disorder, and drug addiction. The dopamine transporter (DAT) mediates reuptake of dopamine
from the synaptic cleft into the pre-synaptic nerve terminus and thereby plays a critical role in
terminating dopaminergic signaling and in maintaining a releasable pool of dopamine.
Amphetamine-like psychostimulant drugs cause a drastic increase in synaptic DA levels by
reverse transport and/or channel-like activity of the DAT.

2

II. Background

A.

Amphetamine-like CNS Stimulants:

1. Overview:
Simple arylalkylamines (AAAs) are known to have widespread abuse potential.
Arylalkylamines are further subdivided into the indolealkylamine (IAAs) and the
phenylalkylamines (PAAs).1 The phenylalkylamines can be further subdivided into the
phenylethylamines and phenylisopropylamines. Amphetamine (AMPH, 1) is the prototypical
central stimulant of the phenylisopropylamine class.1

The synthesis of amphetamine was first reported in 1931 and 1932 by Hartung and Munch2
and Alles,3 respectively. The pressor effects of amphetamine were explained by Piness and
coworkers.4 Amphetamine, due to its ability to promote wakefulness and vigilance, was used in
the treatment of narcolepsy.5 After some time, a study demonstrated that benzedrine (racemic or
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dl-AMPH) administration could improve the academic performance of children with behavioral
disorder.6
This created a foundation for the usefulness of psychostimulants to treat attention-deficit
hyperactivity disorder.7 Amphetamine has also been used to treat fatigue, obesity, Parkinsonism
and for the reversal of CNS depressant toxicity.8 Amphetamine has both peripheral and central
effects.8 Oral administration of amphetamine increases systolic and diastolic blood pressure in
humans and animals.8 It leads to decreased heart rate, and cardiac arrhythmias may result after
large doses.8 As with other sympathomimetic agents, smooth muscle reacts to amphetamine.8
Amphetamine causes relaxation of bronchial muscle, while it contracts the urinary bladder
sphincter.8 In the periphery, the (-)-isomer of amphetamine is equiactive or slightly more potent
than its enantiomer.8 Peripheral effects of amphetamine include mydriasis, tremor, sweating, jaw
clenching, dry mouth and restlessness.9 These actions may be mediated through the release of
norepinephrine, causing indirect sympathomimetic stimulation.9
Amphetamine, a psychostimulant, causes increased alertness, wakefulness, insomnia,
energy and self-confidence in addition to decreased fatigue and appetite, as well as also
enhancing mood, well-being and producing euphoria.10,11 High doses lead to convulsions,
stereotypic movements and psychosis.10,11 When the effect of amphetamine fades, fatigue,
anxiety and tiredness can be seen.10,11 These undesirable symptoms (‘crash’) are seen more when
high or repeated doses are administered, and depression and lethargy can occur.9 Long term
amphetamine use may lead to development of a so called ‘amphetamine psychosis’ characterized
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by psychotic reactions, hallucinations and paranoia.9 Amphetamine has high abuse potential and
can induce dependence, tolerance and withdrawal symptoms.9
Amphetamine has been used as anorectic drug, but it appears to cause unacceptable
tachycardia and hypertension.12 Because amphetamine has high abuse potential, it does not have
US Food and Drug administration indication for the treatment of obesity.12 It was found that in
humans weight loss is due to decreased food intake and not to increased metabolism.8 Drug
induced acute loss of smell and taste have been described; however, dietary restriction is
important for successful weight loss.8 The anorectic action of amphetamine has been reported
due to the activation of dopaminergic and/or β-adrenergic receptors within the perifornical
hypothalamus.13
Additional physiological responses of amphetamine in humans and animals have been
reported as amphetamine-induced hypothermia due to a decrease in metabolic heat production.14
However, at high ambient temperatures, amphetamine induces hyperthermia, which is through
the increase in metabolic rate due to behavioral excitation and cutaneous vasoconstriction.8,14
Amphetamine-induced acute toxic effects are related to its pharmacological actions.15
Amphetamine anorectic activity has been related to an increased risk of pulmonary
hypertension.16 Symptoms of mild toxicity include nausea, vomiting, mydriasis, dry mouth,
sweating, hyperreflexia, bruxism, trismus and palpitations.17 Moderate intoxication by
amphetamine can include hyperactivity, anxiety, confusion, panic attack, psychosis with
hallucinations, tachycardia, hypertension and increased body temperature.17 Sometimes suicidal
and homicidal tendencies can occur.17 Severe intoxication by amphetamine includes delirium,
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coma, seizures, hypertension, dysrhythmia, hyperpyrexia, and renal failure associated with
rhabdomyolysis. Additionally, amphetamine can induce acute ischaemia and haemorrhagic
stroke.17

2. General Structure-activity relationship (SAR):
Most phenylisopropylamine derivatives lack central stimulant activity.18 In general, there
are more “non-amphetamine like” derivatives of amphetamine than “amphetamine like”
derivatives of amphetamine.18 That is, comparatively few amphetamine derivatives retain the
central stimulant action of amphetamine (1), still fewer retain the potency of amphetamine.18
The central stimulant action of amphetamine and amphetamine-related agents is commonly
assessed by measuring their ability to increase the locomotor activity of rodents. That is, these
agents are locomotor stimulants and produce hyperlocomotion. Another means of measuring the
“amphetamine-like” nature of central stimulants is to examine their stimulus properties in
animals trained to discriminate amphetamine, an amphetamine isomer, or a related agent, from
saline vehicle. In this procedure, animals are generally trained to distinguished (i.e.,
discriminate) among the effects produced by one drug to those produced by another. Another
drug, which compares to test drug, may be a different drug, a different dose of the test drug or
vehicle. Studies can be done, when the animals learned to discriminate the training drug from,
for example, vehicle (saline).
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These two measures provide comparable results and offer a convenient approach to
formulation of structure-activity relationships. Using data from such assays, it is relatively easy
to determine the effect of structure modification on amphetamine-like activity.

a. N-Alkylated substituents:
The primary aim of structure-activity studies are to identify those structural features of an
agent that are necessary for or that contribute to activity. It was reported by Woolverton in selfadministration studies of test drugs in cocaine-maintained animals that N-alkylated amphetamine
having substituent groups larger than ethyl are less potent behaviorally than N-methyl (i.e., 2)
and N-ethyl (i.e., 3) substituted amphetamine derivatives and it may be due to decreased ability
of those compounds to release catecholamines centrally.19 It was reported that methamphetamine
(2) produces stimulus generalization to (+)-amphetamine.20 Van der Schoot et al.21 found that
homologation of the N-methyl group of (±)-methamphetamine to ethyl, n-propyl, and n-butyl,
resulted in a rapid decrease in a mouse locomotor activity assay.

b. α-Alkyl substituents:
The methyl group present alpha to the amino group in amphetamine has been previously
established to hinder metabolism by monoamine oxidase by a steric effect.8 The methyl group
7

also makes amphetamine optically active.22 The both enantiomers of amphetamine have been
examined.22 As behavioral stimulants and as releasers of striatal DA, the (+)-isomer of
amphetamine is 5-7 times more potent than the (-)-isomer; however, the (-)-isomer was found to
be equipotent to the (+)-isomer for the release of NE and is similar in potency for the
development of acute psychotic symptoms in humans.22 It is reported that with respect to
peripheral actions, both enantiomers of amphetamine are essentially equivalent in potency, while
the (+)-isomer of amphetamine is seven-fold more active than the (-)-isomer in producing central
effects.23 As both optical isomers of amphetamine produce a similar discriminative stimulus
effect but that one isomer is fairly more potent than the other, Young et al.23 referred to
amphetamine as being stereoselective rather than stereospecific. The removal of the α-methyl
group results in a compound (PEA, phenylethylamine) which does not produce amphetaminestimulus generalization in animals.23
At the α-position of amphetamine, extension of the methyl to an ethyl group dramatically
reduces amphetamine-like activity.24 It has been reported that the (+)-α-ethyl homolog of
amphetamine (i.e., 4) failed to fully substitute for 1 mg/kg of amphetamine in drug
discrimination studies in rats.24 In the same study, the (±)-α-ethyl homolog of Nmethylamphetamine (i.e., 5) was able to substitute to amphetamine but showed one-tenth the
potency of amphetamine.24
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c.

Aromatic substituents:

The introduction of para-chloro substitution (i.e., 6) in the aromatic portion of amphetamine
failed to produce stimulus generalization in drug discrimination studies in rats trained to
discriminate amphetamine from saline, while in the same studies para-fluoro substitution (i.e., 7)
produced stimulus generalization.25 The benzene ring fusion of the b-face (i.e., 1-NAP, 1naphthyl analog of amphetamine, 8) or the c-face (i.e., 2-NAP, 2-naphthyl analog of
amphetamine, 9) of racemic amphetamine failed to produce stimulus generalization in drug
discrimination studies in rats trained to discriminate amphetamine from saline.23 These two
naphthyl analogs were inactive as locomotor stimulants in mice.21
Amphetamine analogs resulting from aromatic substitution are, in general, not
amphetamine-like.23 It was demonstrated by several groups that the 4-hydroxy analog of racemic
amphetamine (i.e., 4-OH PIA, 10) does not produce amphetamine-appropriate responding,26-28
and was inactive in mouse locomotor assays.21 Probably, this is because of the inability of 4-OH
PIA to penetrate the blood-brain barrier.23 O-Methylation of 4-OH PIA results in a less polar
compound, i.e., 4-methoxyamphetamine (PMA, 11).28,29 In two separate studies, it was found
that

PMA produces

amphetamine-stimulus

generalization,

but

is

amphetamine.28,29 PMA was only a weak locomotor stimulant in mice.21,30

9

less

potent

than

The 3,4-methylenedioxy analogs of amphetamine and methamphetamine (MDA, 12 and
MDMA, 13, respectively) have been studied.31 It was found that racemic MDA and MDMA
produce amphetamine-like stimulus effect in rats trained to discriminate amphetamine from
saline.31 However, in the same study, S(+)-MDA produced amphetamine-like effects while R(-)MDA failed to do so.31

The six possible dimethoxy analogs (DMAs) of amphetamine have been evaluated in
amphetamine trained animals.28 It was found that none of these analogs produced complete
amphetamine-stimulus generalization.28 Five possible trimethoxy analogs (TMA’s) of
amphetamine (i.e. 2,3,4-TMA, 2,3,5-TMA, 2,4,5-TMA, 2,4,6-TMA, 3,4,5-TMA) have been
studied.28 2,3,4-TMA and 2,3,5-TMA produced saline-like effects, while the other three analogs
produced disruption of behavior.23 Two of the DMA (i.e., 2,4-DMA and 2,5-DMA) and all TMA
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derivatives of amphetamine were found to produce DOM like hallucinogenic effect in drug
discrimination study.32
Methyl group substitution on the aromatic ring portion of amphetamine results in three
possible methylamphetamines (or tolylaminopropanes; TAPs); i.e., oTAP, mTAP, and pTAP
(14, 15 and 16, respectively). Only oTAP produced amphetamine-like stimulus effects in rats
trained to discriminate (+)-amphetamine from saline, while mTAP and pTAP produced partial
amphetamine-like stimulus effect in the same studies.33 Compounds 14 and 15 were found to be
weak locomotor stimulants in the mouse.21

Wee et al.34 reported the in-vitro potency of p-methylamphetamine (pTAP, 16) and pfluoroamphetamine (7) as releasers of monoamine neurotransmitters (Table 1). They also
reported that as these compounds have the reinforcing effects consistent with full or partial
amphetamine-like discriminative stimulus effects, pTAP and p-fluoroamphetamine have
amphetamine type abuse potential.34 It has been also reported that p-methoxyamphetamine
(PMA, 11) releases dopamine and norepinephrine (Table 1).35 PMA has been known to be used
illicitly in Australia since 1994 and is also becoming popular at rave parties in the United
States.36
11

Table 1. In vitro potency of 4-substituted amphetamine analogs as releasers of monoamine
neurotransmitters.34,35
Drug
p-Methylamphetamine (pTAP; 16)

[3H] NE
EC50(nM)
22.2

[3H] DA
EC50(nM)
44.1

28.0

51.5

p-Fluoroamphetamine (7)
p-Methoxyamphetamine (11)

166

[3H] 5-HT
EC50(nM)
53.4
939
–

867

d. Conformational constraint:
The side chain conformations of various phenylisopropylamines have been studied by
nuclear magnetic resonance, and suggest that in solution, an extended trans-phenylamino
arrangement

is

preferred.29

Some

of

the

conformationally

restricted

analogs

of

phenylalkylamines mimic this conformation.29 For example 2-aminotetralin (2-AT, 17) mimics
this to some extent, while 2-aminoindane (2-AI, 18) to a lesser extent. It was found that 2-AI
(18) and in particular 2-AT (17) are capable of producing various amphetamine-like effects,
including anorexia and locomotor stimulation in animals.29 Four conformationally restricted
analogs, 2-AI (18), 2-AT (17), 6-amino- and 7-amino-6,7,8,9-tetrahydro-5H-benzocycloheptene
(6-AB, 19 and 7-AB, 20, respectively) were studied and it was found that 2-AT (17) is most
similar to racemic amphetamine in potency and may be the conformation that best mimics
amphetamine necessary for producing amphetamine-like stimulant effects, however, compounds
19 and 20 failed to produce amphetamine-like stimulant effect.29 The racemic aminotetralin 17
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produced 10% the locomotor stimulant action of amphetamine in mice, whereas 18 was inactive
at the highest doses tested.21

e. β-Substituents:
Substituents β to the amine have not been well explored.20 Ephedrine (21), an agent that
possesses a β-hydroxy group was found to produce amphetamine-stimulus generalization.20 In
animals, administration of norephedrine (22) produced 70-75% amphetamine-appropriate
responding.20

The β-keto analog of amphetamine, i.e., cathinone (23), is a central stimulant that occurs
naturally.29,37 There is little effect of this carbonyl group on potency.29,37 Cathinone was found to
produce amphetamine-like responding and also like amphetamine, the S-isomer of cathinone is
more potent than the R-isomer.29,37 Cathinone and its derivatives are discussed in more detail in a
later section.
The general structure-activity relationships for amphetamine-like action are summarized in
Figure 1.
13

Figure 1. General structure-activity requirements for producing amphetamine-like central
stimulant and/or discriminative stimulus effects

A. N-alkyl substituents:
-NHCH3 > -NH2 > -NHR (R except CH3)
B. Chiral center:
S(+)-isomer is more potent than R(-)-isomer
C. α-Methyl substituent:
Optimal; removal or extension from methyl reduces potency
D. β-substituents:
=O ≥ -H ≥ -OH
E. Aromatic substituents:
Generally reduce potency
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3. Mechanism of Action:
Amphetamine acts as an indirect monoamine agonist, producing release of norepinephrine,
dopamine and serotonin from presynaptic terminals in the CNS and at the peripheral levels.38,39
Similar results have been reported by Rothman et al.40 in invitro studies (Table 2).

Table 2. Pharmacological profile of amphetamine in DA, NE, and 5-HT release and uptake
inhibition assays.40

Drug

S(+) - Amphetamine
S(+) - Methamphetamine

NE Release

NE Uptake

5-HT Release

5-HT Uptake

DA Release

DA Uptake

EC50

Ki

EC50

Ki

EC50

Ki

(nM)

(nM)

(nM)

(nM)

(nM)

(nM)

38.9

1765

3830

24.8

34

48.0

736

2137

24.5

114

7.07
12.3

Amphetamine interacts with the membrane transporters responsible for neurotransmitter
reuptake and vesicular storage systems.17 It looks like amphetamine is able to enter the nerve
terminal through passive transport or through a reuptake transporter, thus inhibiting the reuptake
of monoamines.17 Once transported inside the neuron, amphetamine reverses the direction of the
transporter causing it to release norepinephrine, dopamine and serotonin to the synaptic cleft.17
Its exact mechanism for producing these effects is unknown. However, an alternative mechanism
explained by De Felice and co-workers, once amphetamine is inside the terminal.41 In addition,
amphetamine is also found to act as a mild inhibitor of the enzymes monoamine oxidase A and
B.17 However, there does not seen to be a relationship between the locomotor actions of these
agents and inhibition of MAO.21
15

The anorectic effect, alerting effect and a part of the locomotor-stimulating action of
amphetamine are presumably through release of NE and DA from noradrenergic nerve
terminals.8 Treatment of the animals with α-methyltyrosine, an inhibitor of tyrosine hydroxylase,
prevents all these effects of amphetamine by inhibiting catecholamine synthesis.8 Particularly in
the neostriatum, release of DA from dopaminergic nerve terminals by amphetamine has been
linked to certain aspects of locomotor activity and stereotyped behavior.8 These behavioral
effects are seen at higher doses, and it can be understood by the need of higher concentration of
amphetamine to release DA from brain slices or synaptosomes in vitro.8
Depletion of serotonin by pretreatment of animals with para-chlorophenylalanine (oral or
intraperitoneal administration) trained to discriminate amphetamine from saline had no
significant effect on amphetamine-appropriate responding.42 Similarly, there was no effect when
animals pre-treated with disulfiram,42 phenoxybenzamine,42 phentolamine,43 atropine43 and
propranolol.42,44,45 Ho and Huang,44 based on the results gained with α-methyl-para-tyrosine
suggested that dopamine might play dominant role in the discriminative stimulus produced by
amphetamine; they also suggested that the stimulus generated by amphetamine might be more
dependent on newly formed dopamine rather than direct interaction of amphetamine with
dopamine receptors. It was found that the dopamine precursor L-DOPA (in combination with a
decarboxylase inhibitor) produced amphetamine-stimulus generalization.23 From the majority of
studies, it was found that apomorphine can produce an effect that is somewhat similar in nature
to that produced by amphetamine.23 This result supports the suggestion made by Ho and Huang,
that a direct dopamine interaction may not be as important as the release of newly synthesized
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dopamine in producing amphetamine stimulus.23,44 Further, D’Mello has suggested that
mesolimbic dopamine system may play a role in the amphetamine discriminative stimulus, based
on electrical brain-stimulation experiments.46
It has been suggested by McMillen that behavioral stimulants can be sub-divided into two
classes of drugs: 1. amphetamine-like direct releasers, and 2. up-take blockers, of dopamine and
norepinephrine.23 Amphetamine-like agents release directly, as well as inhibit reuptake of
dopamine and norepinephrine in both invivo and invitro studies.23 Additional studies were done
with antagonists of particular neurotransmitters to study discriminative stimuli mechanism.23 All
attempts to abolish or attenuate the amphetamine stimulus effects by pretreatment of animals
with serotonin antagonists have been unsuccessful.23 Similarly, tricyclic antidepressants, e.g.
imipramine, nortryptiline, desipramine, failed to block an amphetamine stimulus.47 Supporting
the belief that the stimulus effects of amphetamine are mediated through a dopaminergic
mechanism, certain dopamine antagonists have been found to attenuate amphetamine appropriate
responding; e.g. chlorpromazine,44,47 clozapine,48 pimozide,44 trifluperazine,47,49 thioridazine,47
fluphenazine,49 and haloperidol.42,45,49-51 Thus, it appears that amphetamine is producing
discriminative stimulus, most likely centrally mediated, through a mechanism that involves
dopamine and to a lesser extent norepinephrine.23
It has been reported that chronic misuse of amphetamine may result in long-lasting
impairment of brain function.52 Neurochemical and morphological changes in dopamine or
serotonin neurons in animal studies with response to administration of amphetamine have been
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partially confirmed with brain imaging studies in humans (reduction in dopamine/serotonin
transporters).53-60
Methamphetamine

produces

euphoria

by

elevating

synaptic

dopamine.61,62

Methamphetamine, being lipophilic, may enter nerve terminals by diffusing across the plasma
membrane.61,62 Inside the terminal, methamphetamine binds to the dopamine transporter (see
Table 2) to prevent reuptake and also induces the release of dopamine into the synapse.61,62
Methamphetamine increases dopamine in the cytoplasm which causes neurotoxicity.61,62
Methamphetamine produces these effects via increasing cytoplasmic dopamine through
promoting the activity of tyrosine hydroxylase (which increases dopamine production) and
inhibiting monoamine oxidase (which metabolizes dopamine), while the dominant mechanism is
the effect of methamphetamine on the dopamine transporter, VMAT-2. The combined action of
methamphetamine leads to increased concentration of cytoplasmic and synaptic dopamine.63-71
Methamphetamine, apart from binding to the dopamine transporter and preventing reuptake
of dopamine from the synapse, also reverses the dopamine transporter direction causing the
transporter to release dopamine from the cytoplasm into the synapse.72 The mechanism of this
phenomenon is unknown.72 After 1 h post ingestion, methamphetamine decreases the function of
the vesicular dopamine reuptake transporter.61 The vesicular dopamine transporter normalizes
within 24 h following the ingestion of a single dose of methamphetamine, but after multiple high
doses of methamphetamine, vesicular dopamine transporters only normalize partially.61
In postmortem studies using positron emission tomography (PET), the chronic
methamphetamine use decreases dopamine transporter density in certain regions of brain
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associated with motor and cognitive impairment.72 Though after prolonged drug abstinence,
dopamine transporter density may slowly return to normal, implying that the decrease in
transporter density at the beginning is a neuroadaptive response to the increased synaptic
dopamine.72 While, even if dopamine transporter density returns to normal after drug abstinence,
cognitive deficits may still persist.72
In human methamphetamine users, PET studies show decreased D2 receptor density that
may be due to down-regulation from exposure to increased synaptic dopamine concentrations.73
A redistribution of VMAT-2 due to methamphetamine within the nerve terminal is seen, which
makes the transporter less available to the dopamine molecule, reducing the ability of
cytoplasmic dopamine to move into the protective vesicle.72 In addition, methamphetamine also
leads to release of dopamine from the vesicle into the cytoplasm by two methods.66-69 First,
binding of methamphetamine to VMAT-2 causes vesicular dopamine efflux into the
cytoplasm.66-69 Second, amphetamine, being a weak base, moves across the vesicular membrane
in its unchanged form and accumulates in the acidic vesicle in its charged form (now less able to
penetrate the vesicle membrane).66-69 The acidic pH gradient inside the vesicle provides the
energy for amphetamine accumulation in the vesicle against its concentration gradient.66-69 As
more and more basic amphetamine accumulates into vesicles, the interior of the vesicle becomes
more alkaline.66-69 Due to this alkalinization, the vesicle collapses releasing dopamine into the
cytoplasm.66-69
As vesicular dopamine decreases, it also causes a decrease in dopamine release into the
synapse following depolarization.61 However, the overall concentration of synaptic dopamine
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depends on the action of methamphetamine on the dopamine transporter.61 Methamphetamine
produces selective degeneration of dopamine neuron terminals without cell body loss in neuronal
cell cultures.74 Methamphetamine acidotropic uptake causes osmotic swelling of vacuoles.74
Hyperthermia and oxidative stress may be seen at the initial stage of methamphetamine
neurotoxicity.74
Acidic organelles, like synaptic vesicles, are collapsed by methamphetamine-induced
release of dopamine into the cytoplasm.72 In the cytoplasm, dopamine reacts with molecular
oxygen to form reactive oxygen species (ROS) such as superoxide- and hydroxyl-free radicals
and hydrogen peroxide.72 This whole process is known as intracellular oxidative stress.72 These
ROS lead to damage all cellular biomacromolecules (lipids, sugar, proteins, polynucleotides) and
can also form secondary products that cause damage as well.72 The CNS is more susceptible to
oxidative insult due to high concentration of polysaturated lipids and redox-active transition
metals, as well as poor concentration of antioxidant and high rates of oxygen utilization.72 The
neurotoxic effects seen in animals after methamphetamine administration might be due to
oxidative stress.72
The original dopamine hypothesis of schizophrenia proposed that there is overactivity of the
striatal dopamine systems.75 Additionally, antipsychotic drugs function by blocking dopamine D2
receptors; also, chronic use of psychomotor stimulants can induce psychotic symptoms and this
supports the hyperdopaminergic basis for schizophrenia.75 Strong evidence supporting the
increased dopaminergic activity in schizophrenia has come from imaging studies showing that
the binding of radiolabelled dopamine D2 receptor ligands to D2 receptors is displaced by
20

amphetamine-induced dopamine release, and this effect is increased in schizophrenia.75 One
study showed that a low dose of amphetamine worsens psychosis in patients with schizophrenia,
and the severity of this response was correlated to the estimated release of dopamine.75
The presence of amphetamine sensitization in humans has been obtained indirectly from
observing behavioral and psychological changes in chronic amphetamine abusers.75 The
limitation of this approach is that it is primarily a correlation and it is not possible to rule out that
the observed behavioral changes preceded the start of amphetamine abuse.75 There are some
studies which provide direct evidence for amphetamine sensitization in drug-naїve human
subjects.75 In one study, subjects were exposed to a single dose of amphetamine at three different
time points, with certain pre-selected behaviors being recorded during the first and third
amphetamine exposure.75 After full amphetamine treatment, subjects showed an increased rate of
eye-blink responses and increased motor activity following the third amphetamine exposure, as
compared to their response following the first or second exposures.75 Different studies conducted
by another group provide additional evidence for amphetamine-induced behavioral changes and,
further, showed that amphetamine exposure was associated with a decrease in D2 receptor
radioligand binding ([11C]raclopride) in the ventral striatum following re-exposure to
amphetamine, which indicates enhanced mesolimbic dopamine activity.75

B) Dopamine Transporter (DAT):
Dopamine (DA) is involved in the control of numerous functions including locomotor
activity, reward mechanisms, cognition and neuroendocrine functions.76 In addition, the
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importance of the dopamine system in the CNS has been established based on the finding that
dysfunction of this system is related to a broad spectrum of neuropsychiatric disorders, such as
Parkinson’s disease (PD), schizophrenia, Tourette’s syndrome, attention-deficit hyperactivity
disorder, and drug addiction.76 Even though, there are many important physiological and
pathophysiological functions, dopamine is synthesized and released only from a relatively
discrete number of neurons.77 These dopaminergic neurons are primarily located in the ventral
tegmental area and the substantia nigra from where they extend to areas in the striatum, the
limbic system, and the cortex;77 consequently, it is important to study regulatory mechanisms
relevant to the functioning of DA systems to understand the etiology of various disorders
associated with it and to develop effective therapeutics.78
The DAT mediates reuptake of dopamine from the synaptic cleft into the pre-synaptic nerve
terminus and thereby plays a critical role in terminating dopaminergic signaling and in
maintaining a releasable pool of dopamine.76 The DAT, just like transporters for serotonin
(SERT), norepinephrine (NET), GABA, glycine, creatine, taurine, and proline, is a member of
Na+/Cl--dependent transporter family. The DAT contains 12 transmembrane domains having
both amino- and carboxy-termini projected into the cytoplasm.79 DATs transport DA through
sequential binding and cotransport of two Na+ ions and one Cl- ion in association with one
molecule of DA.79 Expression of DAT is exclusive to the dopaminergic nerve bodies and
terminals and can serve as a selective marker of these dopaminergic neurons.79 In the brain, DAT
is expressed highest in the striatum and nucleus accumbens followed by the olfactory tubercle,
hypothalamic nuclei, and pre-frontal cortex.79 DAT expresses in peripheral areas including the
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retina, gastrointestinal tract, lung, kidney, pancreas, and lymphocytes.79 DAT is mostly localized
perisynaptically rather than in the synaptic compartment based on ultrastructural analysis which
supports the previous estimations that reuptake of dopamine occurs at a distance from release
site.79
DAT-KO mice are hyperactive, dwarf, and display cognitive and sensorimotor gating
deficits, and sleep dysregulation.80 Normal social interaction has been seen in the mutant mice,
but DAT-lacking females show an impaired capability to care for their offspring, most probably
due to anterior pituitary hypoplasia-related hormonal dysregulation.80 DAT is the major target of
the widely abused psychostimulant drugs cocaine and amphetamine.76 But, these drugs act
through different mechanisms.76 Cocaine binds to the DAT substrate binding site and blocks
transporter activity as a competitive inhibitor, while amphetamine is a transporter substrate able
to promote DAT-mediated dopamine release.76
In DAT-KO mice, due to disruption of clearance of the released DA, there is about a 300fold increase in the lifetime of DA in the extracellular space, as shown by cyclic voltametry
measurements, and in vivo microdialysis at least five-fold elevation in the basal extracellular DA
levels.79 In addition, a profound depletion of intraneuronal dopamine stores (20-fold) and an
attenuated level of evoked dopamine release (4-fold) was found in DAT-KO mice. Due to lack of
dopamine-uptake-mediated recycling, the amount of dopamine in the striatum depends on the
rate of its ongoing synthesis in these mice.79 Inhibition of tyrosine hydroxylase (TH), the ratelimiting enzyme in DA synthesis, essentially eliminates dopamine in the striatum of mutant
mice.79 Therefore, in DAT-KO mice, the DA levels are represented basically by a newly
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synthesized pool.79 Thus, in the normal situation, major DA storage pools in the presynaptic
striatal terminals must be regulated by DAT-mediated DA recycling based on these
observations.79
Dopamine receptors undergo regulation due to the persistent increased dopaminergic tone.81
Due to a marked desensitization of the major autoreceptor functions, there is loss of functional
activity of autoreceptors observed as response to regulation of neuronal firing rate and DA
release and synthesis.81 In DAT-KO mice, D1 DA receptors are down-regulated by
approximately 50% in the striatum, but paradoxically, the postsynaptic DA receptors belong to
certain populations that appear to be supersensitive.79
In addition to DAT function in the regulation of efficacy of DA transmission, it plays a
major role in neurotoxic reactions induced by large doses of amphetamine derivatives and
dopaminergic neurotoxins.79 In experimental animals Parkinson’s disease (PD) can be modeled
by toxic lesions of dopaminergic neurons using MPTP.79 MPTP-induced death of dopaminergic
neurons is due to its reactive metabolite 1-methyl-4-phenylpyridium (MPP+) which is known to
transport into dopaminergic terminals through the DAT.82 As per prediction, a lack of MPTP
neurotoxicity was found in DAT-KO mice.79 In DAT-KO mice, a significant reduction of
dopaminergic neurotoxicity and lethality was observed even after administration of a neurotoxic
regimen of methamphetamine-related compounds.79 Thus, it is clear that the DAT is critical for
the degeneration of presynaptic DA neurons primarily by allowing entry of toxic compounds into
the dopaminergic neurons.79
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C. Regulation of the Dopamine Transporter:
Numerous studies have been conducted to understand the cellular mechanisms responsible
for regulating the availability and activity of the DAT in the presynaptic membrane.76 Several
proteins have been identified, including kinases, receptors, and scaffolding protein, that modulate
the catalytic activity of the DAT or its trafficking by their interaction with the DAT.76
DAT is exposed to dynamic regulation in the plasma membrane.76 This regulation may be
important in the sense that it provides the strength to dopaminergic signaling which can be either
attenuated or intensified.76 The regulatory effect of protein kinase C (PKC) activation has been
studied.76 It has been shown in various studies involving several heterologous cell lines
transfected with DAT that activation of PKC by phorbol esters, like phorbol 12-myristate 13acetate, down-regulate DAT capacity.83-88 The sustained DAT down-regulation due to PKC
activation results most likely from DAT endocytosis.76 The PKC-induced inactivation of DAT is
independent of DAT phosphorylation by PKC.76 In PKC-activated DAT down-regulation,
involvement of another post-translational modification, ubiquitination, has been seen in recent
studies.76 Ubiquitination regulating protein homeostasis is a widespread post-translational
modification.76 In studies conducted by Miranda et al.,89 it was shown that DAT is ubiquitinated
and this is augmented upon phorbol 12-myristate 13-acetate stimulation. The ubiquitination was
dependent on the presence of three lysines at the intracellular N-terminus (lysine 19, lysine 27,
and lysine 35) of DAT and mutation of these residues to arginine residues essentially diminished
DAT down-regulation.76
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In the DAT C-terminus, a motif has also been shown to be essential for DAT
internalization.90 The motif consist of a stretch of 10 residues of amino acids (587-596 in hDAT)
which upon mutation to alanines caused impairment of both constitutive and PKC mediated
DAT internalization.90 Additionally, it was reported that substitution of only 587-590 residues
with alanine was sufficient to diminish PKC-associated DAT down-regulation and increase
constitutive DAT internalization.91 This study suggested that the stretch of four residues is part
of an endocytosis braking mechanism, which is relieved upon PKC stimulation.91
MAPK has been found to regulate DAT; for example, in transfected HEK293 cells and in
striatal synaptosomes MAPK inhibitors were shown to decrease dopamine uptake.92 This might
be due to alteration in DAT transport capacity and redistribution of DAT from the plasma
membrane to the cytosol.92 Moreover, DAT regulation might be subject to regulation by
phosphatases, as it has been reported that DAT exists in a complex with protein phosphatase
2A.93 DAT substrates and inhibitors are also involved in regulation of DAT surface levels.76
Both amphetamine and cocaine promote internalization of DAT whereas cocaine increases DAT
surface levels.76 The mechanism behind this and responsible protein-protein interactions are still
poorly understood.76
Lewy bodies, aggregation of α-synuclein in protein inclusions, are characteristic for the
pathology of Parkinson’s disease (PD).76 In PD pathogenesis a role for synuclein is supported by
the observation that point mutations in the α-synuclein gene as well as multiplications of the wild
type gene have been identified in a rare familial form of PD.76 It has been reported that αsynuclein binds directly to the C-terminal tail of DAT and was shown to involve the last 22
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amino acids of DAT and the non-amyloid beta component domain of α-synuclein.94 An increase
in dopamine-uptake was observed in Ltk-mouse fibroblasts in cells co-expressing α-synuclein
and DAT compared to cells expressing α-synuclein and DAT alone and dopamine-induced
cellular apoptosis was also observed.94 The coupling of α-synuclein to DAT was confirmed by
Wersinger and Sidhu;95 however, they observed a reduction in dopamine uptake upon overexpression of α-synuclein in the Ltk-cells. These controversial results might reflect differences in
the level of α-synuclein over-expression, similar results were obtained in the regulation of NET
by α-synuclein.96 So far no alteration in DAT function has been observed in α-synuclein knockout mice.76
Two studies have given evidence that the dopamine D2 receptor short variant (D2Rs),
presynaptic autoinhibitory receptor expressed in dopaminergic neurons is likely to regulate DAT
function.97,98 D2Rs directly interacts with DAT; this has been seen in co-immunoprecipitation
and GST fusion protein pull-down experiments in striatal tissue extracts.98 The evidence suggests
that the interaction depends on residues 1-33 in the DAT N-terminus and residues 311-344 in the
D2Rs third intracellular loop.98 DAT with over-expressed D2Rs in a cell line increases dopamine
uptake by 30-60%, mostly through an increased DAT surface expression and independent of the
presence of D2R ligands.98 In addition, the dopamine D3 receptor, another D2-class receptor, was
shown to up-regulate DAT surface expression in transfected HEK293 cells upon activation;
however, the interaction of DAT and the D3 receptor was not investigated.99
The orphan receptor GPR37 has also been recently suggested to interact with DAT.100 DAT
function was increased in GPR37 knock-out mice through an increased DAT expression, and
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was suggested to involve an interaction between DAT and GPR37.100 In transfected HEK293
cells, the putative physical interaction was only supported by co-immunoprecipitation
experiments and immunofluorescence co-localization.100 Thus, additional studies have to be
conducted to explore the significant of a putative DAT/GPR37 interaction.76
The scaffolding proteins are multiple protein interaction domains, serving as assembly
modules and glue together the proper interaction partners.76 This includes proteins connecting
membrane to their downstream signaling partners or anchoring them in the right cellular
microdomains.76 Various studies have been done to investigate putative proteins and protein
domains involved in DAT scaffolding.76 The most widespread protein domains known as PSD95/Discs-large/ZO-1 homology (PDZ) domains in cellular scaffolding processes have been
investigated.76 The C-terminus of DAT has a canonical PDZ-binding sequence and in a yeast
two-hybrid screen the C-kinase 1 (PICK 1) was discovered as a DAT interaction partner.101 Coimmunoprecipitation experiments in brain tissue extracts suggested that this interaction promotes
DAT surface expression and induces a clustering phenotype in transfected cells.101 However, this
finding was challenged by Bjerggaard et al.,102 who showed that although PICK 1 binds the
extreme DAT C-terminus, the interaction does not play a role in ER export and surface targeting
of the transporter. C-Terminal residues of DAT are important for proper membrane targeting of
DAT, however, mutations in DAT were identified, which was shown to disrupt PDZ domain
interactions without affecting surface targeting, and mutations were recognized that disrupted
surface targeting without affecting PICK 1 binding.102 Thus, the functional significance of the
DAT-PICK 1 interactions still remained to identify.76
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D. Classes of Drugs acting through DAT:
Psychostimulants are agents which enhance extracellular DA concentration. There are two
classes of psychostimulants based on their mechanism by which they affect the DAT:78 1) uptake
blockers and 2) releasers.
These classes of psychostimulants are based on their effects on acute neurotransmitter flux
through the DAT.78 However, releasers may have some ability to act as uptake blockers and
uptake blockers can have some ability of releasing neurotransmitter, but this general separation
of drugs into two classes helps to distinguish the pharmacological profiles of the most commonly
used psychostimulants.78

1. Uptake blockers:
Based on their effect on DAT, cocaine and methylphenidate (MPD) are the bestcharacterized uptake blockers.78 Cocaine and MPD share common binding on the DAT system102
and their mechanism of action on the DA systems are similar.78
The primary mechanism of action of cocaine and MPD is to bind directly and inhibit the
transport of DA through the DAT.104 There is an increase in extracellular DA levels due to
blockade of DAT activity and is not related with selective longterm toxicity to the nigrostriatal
DA pathway.105 It has been seen that there is an increase in DA uptake in synaptosomes prepared
from treated rats, a preparation from which the drug has been presumably washed out, due to
blockade of DAT by cocaine.106 This may be due to the increased recruitment of DATs to the
plasma membrane.78 After cocaine administration in rodents and cell lines, respectively, this
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acute increase in DA uptake and plasmalemmal surface expression was observed, likely due to
maintain normal synaptic DA function.78
In humans, those who have acutely enhanced synaptic DA levels through the use of cocaine,
enhanced DAT function is observed in synaptosomes from cryoprotected human brain.107 The
development and expression of cocaine addiction is most likely based on the combination of an
initial DAT blockade and a subsequent increase in DA uptake.78 The drug dependence, perhaps
developed by an overabundance of extracellular DA due to DAT blockade which initiates a
compensatory increase in DAT activity, leads to a deficit of extracellular DA.78

2. Releasers:
Amphetamine-like psychostimulant drugs that are classified as “releasers” include
amphetamine (1), methamphetamine (METH, 2), and 3,4-methylenedioxymethamphetamine
(MDMA, 13).108,109 These releaser drugs increase DA release by disrupting vesicular pH
gradients allowing vesicular DA to redistribute into the cytoplasm.108,109 As cytoplasmic DA
levels rise, DA leaves the neuron through reverse transporter and/or channel-like activity of the
DAT,110, 111 which causes a drastic increase in synaptic DA levels.78
In rats, injection of METH (2) in a single high-dose (10 mg/kg) rapidly (within an hour) and
reversibly decreases the amount of DA taken up into synaptosomes developed from treated
rodents.112 Rapid exposure to amphetamine reduces plasma membrane-associated DAT
demonstrated by data from cell lines expressing the DAT, most likely representing a significant
shift of the DAT protein to the cytosolic fraction.113 It is difficult to extrapolate the time course
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of DA release via the DAT and a reduction of DAT on the cell surface in vivo, while, most
probably, releasing drugs enhance initial DA release followed by a removal of DAT from the cell
surface.78

Table 3. Pharmacological profile of selected agents in dopamine, norepinephrine and 5-HT
release assays.114
Drug

S(+)-Amphetamine
S(+)-Methamphetamine
S(-)-Methamphetamine
S(+)-MDMA
S(-)-MDMA

Release
NET
EC50(nM)
7.07
12.3
28.5
136
560

Release
DAT
EC50 (nM)
24.8
24.5
416
142
3700

Release
SERT
EC50 (nM)
1765
736
4640
74
340

With higher doses of releasers, the effects become more complicated and cause persistent
deficits in striatal DA systems (such as 4x10 mg/kg/injection of METH at 2-hour intervals).115
As compared to single injection of METH, multiple high-dose administration leads to a rapid
(within an hour after final METH injection) decrease in DAT activity; however, this reduction in
DAT is substantially greater and may be associated to persistent dopaminergic deficits.115 The
mechanism behind this releaser-induced toxicity is not completely understood, but most likely
increased DA, hyperthermia and oxygen radicals contribute to this phenomenon.115
In addition to changes in DAT activity induced by releasers, it has been demonstrated that
higher doses of these drugs cause physical alterations in DAT, most likely a neurotoxic regimen
of METH induces DAT complex formation.116 Whether these protein complexes at the site of
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production are homomeric or heteromeric are not clear, however, when neurotoxic regimens of
METH are administered.78 These complexes are seen to be associated with toxicity as their
production is dependent on DA, hyperthermia, and reactive species,117 which are requisite factors
for the METH-induced persistent DA deficits in the striatum. The functional influence of
METH-induced DAT complex formation still needs to be determined.78

E. Cathinone:

1. Historical Background:
“Khat (Catha edulis, Celestraceae) is a flowering plant, indigenous to tropical East Africa
and the Arabian Peninsula. The origins of the plant are often argued. Many believe its origins
are Ethiopian, others state that khat originated in Yemen before spreading to Ethiopia and the
nearly countries Arabia, Kenya, Somalia, Uganda, Tanzania, Malawi, Congo, Zambia,
Zimbabwe and South Africa; it has also been found in Afghanistan and Turkestan. The ancient
Ethiopians considered the plant a “divine food”, while the Egyptians used the plant for more
than its stimulant effects. They used it in a metamorphic process to transcend into “apotheosis”,
thus the human being was made “god-like”. The earliest documented description of khat dates
back to the Kitab al-Saidana fi al-Tibb, an 11th century work on pharmacy and material medica,
written by Abu Rayhan al-Biruni, a Persian scientist.”118
“The name Catha edulis was first given to the plant by Forsskal in 1775, and this name has
since been used by most authors. (other locally used names are: qut, q’ut, kat, kath, gat, chat,
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tschat, miraa, and murungu; the dried leaves of the plant are known as Abyssinian tea, Arabian
tea or Bushman tea). Catha edulis is a shrub or decorative tree growing 1-25 m tall and is
widely distributed in Africa. The leaves are elliptic to oblong, pendulous, leathery, bright green
and shiny above, paler below with an evenly toothed margin. They are 5-10 cm long and 1-4 cm
wide. Khat grows in habitals varying from evergreen submontane forest to deciduous at 8002000 m altitude and is now indigenous in Ethopia, Kenya, Uganda and Tanzania, and from East
Congo (formerly Zaire) southward to South Africa. Very recently it has been introduced to
Somalia.”118
Chewing leaves of the khat plant, in areas in which the plant is indigenous, is a habit due to
its pleasurable stimulant effect.119-121 It has been estimated that about 5-10 million people chew
the leaves every day.119-121 For example, in Yemen 60% of the males and 35% of the females
chewed khat leaves for long periods of their lives.119-121 Khat leaf chewing induces stimulant
effects and produces a certain degree of euphoric effect.119-121 It was reported by Alles et al.122
that quantitative comparisons in man of the central stimulant aspects of khat plant material, its
aqueous extracts, and its detannated extracts, gave results that corresponded to the amount of
dextro-norpseudoephedrine isolated. These desirable effects are only produced by fresh leaves,
so that until the present time the chewing habit has remained in those areas where the plant is
indigenous.119-121 After harvesting, khat is sold as a bundle of twigs, stems and leaves, and is
wrapped in banana leaves to preserve freshness.118 During the past few years because of rapid
and relatively inexpensive transportation, the drug has been reported in Great Britain, Italy, The
Netherlands, Canada, Australia, New Zealand, the USA, and Hungary.118
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Khat has been traditionally used as a socializing drug and this is still the case.123 In the
countries where it grows, it is used as a recreational drug, also it may be used by farmers and
agricultural and other laborers for decreasing physical fatigue and by drivers and students for
increasing attention.123 At the age of 10, children often start chewing khat.123 At present, khat is
so popular in Yemen that about 40% of the country’s water supply goes towards irrigation of
khat plants.123
In the USA a kilo of khat is being sold for $300-500 and a bundle of leaves sold for $3050.124 It has been seen that there is an increase in use of khat in the upstate New York area.124
The USA Drug Enforcement Administration (DEA) executed operation Somalia Express in July
2006, an 18-month investigation that resulted in the coordinated takedown of a 44-member
international trafficking organization that was responsible for smuggling 25 tons of khat from the
Horn of Africa to the USA, which was worth more than $10 million according to DEA
estimation.124
It is reviewed that in 1887, Flücklger and Gerock first attempted to isolate the active
principle of the plant.119 It is reviewed that Wolfes identified norpseudoephedrine in khat leaves
in 1930 and in 1941, Brücke stated that the amount of norpseudoephedrine in khat was
insufficient to account for the symptoms produced.118 Due to this statement, the plant was
reinvestigated and studies resulted in isolation of the keto-analog of norpseudoephedrine from
khat leaves, and cathinone (β-keto-amphetamine; 23) was suggested as the name for this
alkaloid.125-129 The khat plant contains the phenylalkylamine cathinone ((-)-cathinone) and the
diastereoisomers cathine (1S,2S-(+)-norpseudoephedrine or (+)-norpseudoephedrine) and
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norephedrine (1R,2S-(-)-norephedrine).130 These phenylalkylamines are structurally similar to
amphetamine and noradrenaline.130 The khat plant contains the (-)-enantiomer, but not the (+)enantiomer of cathinone.130
Cathinone is chemically unstable, undergoes decomposition reactions after harvesting and
during drying or extraction of the plant material.118 Cathinone generally decomposes to a dimer
(3,6-dimethyl-2,5-diphenylpyrazine) and most likely to some small fragments.131 This is the
reason why users prefer the fresh leaves as cathinone is the psychoactive component of khat.118
The content of phenylalkylamines in khat leaves varies within wide limits.118 A 100 g sample
khat of leaves contains, on average, 36-114 mg cathinone, 83-120 mg cathine and 8-47 mg
norephedrine.132-134

2. Pharmacology:
(-)-Cathinone has a positive inotropic and chronotropic effect in isolated guinea pig atria.135
In whole animal, (-)-cathinone and (+)-amphetamine were found equipotent in increasing the
heart rate when injected i.v. at a dose of 1 mg/kg.135 It was reported that (-)-cathinone has a
pressor effect in anaesthetized cats; when administered i.v. 1 mg/kg resulted in a transient rise in
the blood pressure by 30 to 35 mmHg.130
As like (+)-amphetamine, (-)-cathinone produces hyperthermia in rabbits after its injection
and reduces the body temperature of rats previously exposed to a cold temperature.135 (-)Cathinone produced long lasting analgesia in rats using the tail-flick test, and the duration of
analgesic effect was dose related.130
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It has been reported that s.c. administration of cathinone in rats increases the locomotor
activity of the animals, and that (±)-cathinone had a potency approaching that of (+)amphetamine.135 Van der Schoot et al.21 found (±)-cathinone to produce half the maximal
locomotor effect of (+)-amphetamine in mice, but specific doses were not provided.
Quantitatively, in another study using mice, the locomotor activity of (-)-cathinone was oneseventh of the potency of (+)-amphetamine.136 The dose-response curve of cathinone’s effect on
locomotor activity was observed to be an inverted-U shape, which is typical of stimulants of the
amphetamine type.130 Reserpinization only partially antagonized the locomotor response of mice,
which is similar to that for (+)-amphetamine hypermobility.137 In order to find out whether the
stimulation of locomotor activity involves activation of dopamine receptors as in the case of (+)amphetamine, the effect of dopamine receptor antagonists, like haloperidol, spiroperidol and
pimozide were investigated.137 It was seen that dopamine receptor antagonists blocked the
locomotor response to (-)-cathinone; this finding is in agreement with those for (+)amphetamine.137
Pretreatment of the animals with the catecholamine synthesis blocker α-methylparatyrosine,
completely blocked the induction of stereotyped behavior by (-)-cathinone.135 However,
pretreatment of animals with the dopamine receptor antagonist haloperidol reduced biting and
licking movements induced by cathinone.138
(-)-Cathinone has been reported to act as anorectic compound in behavioral experiments
with monkeys.131 In rats, intracerebroventricular injection of (-)-cathinone inhibits food intake to
a greater extent than amphetamine.131 In rats, it has been reported that i.p. injection of racemic
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cathinone resulted in reduced food intake, and that chronic administration led to a decrease in
body weight.139 In this study, (+)-amphetamine was seen more potent than cathinone.139
The similarity of cathinone to amphetamine was shown by Rosecrans et al.37 who reported
that racemic cathinone could be substituted for (+)-amphetamine in rats trained to distinguish
between a placebo and (+)-amphetamine. When administered cathinone, the animals responded
the same as if they had been given (+)-amphetamine, and this response was dose related.37 It has
been seen that cathinone and (+)-amphetamine produced the same response pattern and were
equipotent in drug-discrimination studies in rats trained to discriminate (+)-amphetamine from
vehicle.29 Cathinone has a more rapid onset of action compared to amphetamine based on drug
discrimination experiments.140 (-)-Cathinone (i.e., S(-)23) is several times more potent compared
to (+)-cathinone (i.e., R(+)23) in producing central stimulant and drug discriminative stimulus
effects, while (+)-amphetamine (i.e., S(+)1) is more potent than (-)-amphetamine (i.e., R(-)1).141
However, (-)-cathinone (S(-)23) and (+)-amphetamine (S(+)1) have the same absolute
stereochemistry (i.e., S), so that S(-)-cathinone (S(-)23) structurally resembles S(+)-amphetamine
more than R(-)-amphetamine (R(-)1).141 Cathinone’s discriminative stimulus effects were not
blocked by the serotonin antagonist BC105/B.126 It was reported by Glennon et al.142 that rats
trained in a two-lever drug-discrimination procedure were less likely to distinguish between (-)cathinone (S(-)23) and quipazine, a serotonin receptor agonist, than between (+)-amphetamine
(S(+)1) and quipazine. However, it was found that chronic treatment of rats with racemic
cathinone reduces the level of dopamine in several brain areas but does not affect the level of
serotonin.125
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In monkeys trained to press a lever for cocaine injection, the animals continue to respond at
high rates when the training drug was replaced with (-)-cathinone.143 In this study, the
reinforcing effect of (-)-cathinone was reported to be greater than (+)-amphetamine.143 Cathinone
may produce rates of responding higher than amphetamine based on self-administration
experiments with monkeys.129
It has been reported that cathinone modified brain catecholamine turnover, but to a lesser
extent than (+)-amphetamine.37 In mice, pretreated with (-)-cathinone, the turnover of dopamine
increased by 32%, but that of norepinephrine was practically unaffected.144 In rats, repeated
administration of racemic cathinone produced a long-lasting depletion of dopamine in several
brain regions, with no effect on the level of norepinephrine.144 It has been found in an assay
system involving beef monoamine oxidase and benzylamine as a substrate, that (-)-cathinone
was considered more potent in inhibition of monoamine oxidase than racemic amphetamine.145
There are two possible mechanism of cathinone action: that its effects may be produced by
a blocking of the reuptake of, primarily, physiologically released dopamine, and another
possibility would be that cathinone acts by inducing the release of, primarily, presynaptic storage
dopamine, a mechanism considered of importance for amphetamine on dopaminergic
transmission.146 Therefore, the efflux of radioactivity from rabbit caudate nucleus prelabeled
with 3H-dopamine induced by (-)-cathinone was studied.147 It was observed that superfusion of
the tissue with 4 μM (-)-cathinone resulted in a rapid and reversible increase of efflux of
radioactivity which was comparable to that produced by the same concentration of (+)-
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amphetamine.147 A releasing effect for racemic cathinone also was found in 3H-dopaminepreloaded synaptosomes obtained from rat neostriatum.144
In conclusion, based on various studies, it is known that cathinone is in a real sense a
natural amphetamine while being the major psychostimulant constituent of khat.129 See Figure. 2
for a structural comparison of these and related agents. It might be noted that there are some
discrepancies in the studies that have used cathinone and these can probably be attributed to
species differences, or the use by various investigators of either (±)- or (-)-cathinone. For
example, whereas (-)-cathinone is a locomotor stimulant, (+)-cathinone decreases the locomotor
action of mice up to a dose of 100 μmoles/kg; (±)-cathinone produces intermediate results.136
Nevertheless, cathinone has a pharmacological profile same as that of amphetamine: cathinone
shows the same actions of amphetamine on the CNS as well as its sympathomimetic effects.129
The major difference among the two drugs is the shorter duration of the action of cathinone; its
reduced stability promotes a more rapid inactivation.129

Figure 2. Stereochemistry of amphetamine (1), methamphetamine (2), cathinone (23) and
methcathinone (24) isomers.
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3. Cathinone Analogs:
Cathinone/methcathinone

analogs

are

structurally-related

to

amphetamine/

methamphetamine derivatives but bear an additional β-keto group. The structural relationships
among representative examples of these agents are shown in Figure 3.

Figure 3. Structural relationship between amphetamine (AMPH), methamphetamine (METH)
and their β-keto or cathinone (CATH) or methcathinone (MCAT) counterparts.

Glennon et al.136 examined the effects of various substituent groups on racemic cathinone
on locomotor activity. They found that 2-methoxy, 4-methoxy (i.e., 32), 2,4-dimethoxy and 4fluoro (i.e., 29) derivatives of racemic cathinone failed to produce locomotor stimulant
activity.136 They also found that the α-desmethyl analog of cathinone had no significant effect on
locomotor activity.136 Furthermore, it was reported that stimulus generalization occurs between
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(+)-amphetamine and cathinone regardless which drug is used as the training drug.148 2Aminotetralone, a conformationally restricted cathinone (ringcathinone), produced salineappropriate responding in rats trained to discriminate (+)-amphetamine from saline.148 In the
same studies, N,N-dimethylaminopropiophenone and α-desmethylcathinone failed to produce
(+)-amphetamine-like effects.148

Cathinone is a naturally occurring amphetamine-like substance and both share similar
pharmacological effects.141 If parallel structural modification results in parallel changes in action
and potency, N-monomethylation of amphetamine should enhance potency. That is, Nmonomethylamphetamine (methamphetamine) is twice as potent as amphetamine as central
stimulant. Hence, N-monomethylation of cathinone, not surprisingly, should be more potent than
cathinone both as locomotor stimulant in mice and in tests of stimulus generalization in rats
trained to discriminate (+)-amphetamine from saline vehicle. This was found to be the case.149
Glennon et al.149 termed this substance methcathinone (24).
N-Methylcathinone was first synthesized by the Germans150,151,152 and the French153 as well
as Adams154 and co-workers in the late 1920’s as an intermediate in the synthesis of ephedrine
and was first mentioned by Chen et al.155 in 1926. The two isomers of N-methylcathinone were
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first reported in 1936156 and the (-)-isomer was thereafter patented as an analeptic.157,158 It was
found that methcathinone is more potent than cathinone both as a locomotor stimulant and in test
of stimulus generalization using rats trained to discriminate (+)-amphetamine from saline.141 In a
locomotor stimulant test in mice, S(-)-methcathinone (i.e., S(-)24) was five times more potent
than its optical isomer.149 S(-)-Methcathinone (S(-)24) was nearly three times more potent than
R(+)-methcathinone (i.e., R(+)24) with racemic methcathinone potency falling between the
potencies of the two isomers in drug discrimination studies using cocaine-trained rats, and S(-)methcathinone (S(-)24) was more potent than R(+)-methcathinone (R(+)24) in same test using
S(+)-amphetamine-trained animals.141 Thus, all three results are in agreement that S(-)-cathinone
(S(-)23) is more potent than R(+)-cathinone (R(+)23) where the S-isomer of amphetamine is
more potent than R-isomer of amphetamine.
In 1997, Glennon159 and co-workers wished to determine whether structural modification of
cathinone paralleled the effects observed upon structural modification of amphetamine. They
tested several N-alkylated and methylenedioxy-substituted analogs of cathinone and compared
them with amphetamine analogs. Similar to amphetamine, N-monomethylation of cathinone was
found to retain potency, while any further increase in alkyl chain length was found to decrease
potency.159 It was surprising for them that (+)-N,N-dimethylamphetamine resulted in a 7-fold
decrease in potency over (+)-methamphetamine (i.e., S(+)2) in producing (+)-amphetamine
appropriate responding in rats trained to discriminate (+)-amphetamine from saline, while (±)N,N-dimethylcathinone (36; see Table 5) was found only slightly (1.6 fold) less potent than
racemic methcathinone.159 Based on the knowledge that incorporation of a 3,4-methylenedioxy
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group can change amphetamine from a CNS stimulant to a combination of CNS stimulant,
hallucinogenic (DOM-like) and empathogenic (MDMA-like) agent (i.e. MDA, 12), Glennon and
colleagues studied the 3,4-methylenedioxy derivatives of cathinone and methcathinone.159 It was
found that the 3,4-methylenedioxy analog of cathinone (i.e. MDC, 34), failed to completely
substitute for (+)-amphetamine or DOM, so introduction of a carbonyl group resulted in an agent
which no longer acts like its parent compound (MDA, 12).159 The 3,4-methylenedioxy analog of
methamphetamine, MDMA (13) shows amphetamine-like effect but lacks DOM-like
character.159 N-Monomethylation of MDC (34) results in an agent (i.e. MDMC, 35) which
behaves similar to MDMA (13).159 It was interesting that, both MDC (27) and MDMC (35) show
MDMA-like properties in MDMA-trained rats.159 It was found that with MDMA (13),
introduction of carbonyl group resulted in a compound (i.e. MDMC, 35) which is less potent
(about two-fold).
MDMC (35) was first patented by Jacob III et al.160 and they called this substance
methylone. Cozzi et al.161 have compared methcathinone (24) and methylone (MDMC, 35) to
methamphetamine (2) and MDMA (13) for their abilities to inhibit 3H-serotonin, 3H-dopamine,
and 3H-norepinephrine uptake via the plasma membrane uptake transporters and they also tested
inhibition of 3H-serotonin uptake by the vesicular monoamine transporter, VMAT-2 (Table 4).
They found that methcathinone (24) and methylone (35) were as potent as the respective
methamphetamine (2) and MDMA (13) at inhibiting monoamine accumulation, and all of the test
drugs were more potent at the dopamine transporter than at the norepinephrine transporter.161 At
the serotonin uptake carrier, methcathinone (24) and methylone (28) were one-third as potent as
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methamphetamine (2) and MDMA (13), respectively.161 They found that methcathinone (24) and
methylone (35) are highly selective for the plasma membrane catecholamine transporters and
show decreased potency at VMAT-2 compared to methamphetamine (2) and MDMA (13),
respectively.161
Table 4. IC50 values (μM) for drug inhibition of monoamine uptake.161
Drug

[3H] 5-HT

[3H] DA

[3H] NE

VMAT2
([3H] 5-HT)

(±)-Methcathinone (24)

34.6

0.356

0.511

112.1

(±)-Methamphetamine (2)

11.6

0.467

0.647

10.9

(±)-Methylone (35)

5.75

0.819

1.220

165.6

(±)-MDMA (13)

2.14

0.478

1.380

12.7

Methylone (35) abuse was first reported in 2004 as a liquid solution sold as a vanillascented odorizer.162 Recently, it has been found that methylone is sold in plastic tubes containing
5 mL of liquid called Explosion via the internet and in head shops.163 There is no significant
clinical literature on the effects of methylone (35).164
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Mephedrone (4-methylmethcathinone; 27) is a cathinone derivative, which elicits a
stimulant effect like amphetamine (1), methamphetamine (2), cocaine and MDMA (13).165
Recently, it has drawn media attention due to its link to a number of fatalities.166 Sachez
described the first synthesis of mephedrone (27) in 1929.167 Due to the cathinone (23) ban,
chemist started altering the structure of cathinone (23) to produce related unscheduled agents.166
In May 2003, the first online report on mephedrone (27) appeared, however, the online
availability and related popularity of mephedrone (27) started in 2007.166 The national Addiction
Centre in London conducted research involving 2,295 readers of the dance magazine ‘Mixmag’
and reported that 41.7% of surveyed people had tried mephedrone (27) and 33.2% had used it
during the previous month, showing its popularity among ‘clubbers’ and making it the sixth most
popular drug, after tobacco, alcohol, cannabis, ecstacy and cocaine.168 In the UK, the Advisory
Council on the Misuse of Drugs recommended inclusion of mephedrone (27) in the Misuse of
Drugs Act 1971 under class B and as a result, it was made a controlled drug (class B) on the 16th
of April 2010.169
Mephedrone (27) is the N-methyl cathinone analog of pTAP (16). It has been reported that
pTAP produces partial stimulus generalization in rats trained to discriminate (+)-amphetamine
from saline.33 Table 1 shows the potency of pTAP (16) as a releaser of monoamine
neurotransmitters.34 pTAP (16) was found to produce positive reinforcing effects in monkeys.34
In 2010, pTAP (16) was detected in seized amphetamine mixture containing amphetamine,
caffeine, di-(phenylisopropyl)amine (DPIA) and some by products.170 There is not much known
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about its N-methyl analogs 4-methylmethamphetamine (25) and 4-methylcathinone (26) which
are, respectively, methamphetamine and cathinone counterpart of mephedrone (27).
Since 2006, an additional 10 cathinones have been reported in the European Union (shown in
Table 5).169
Table 5. List of cathinones reported in Europen Union.169

R1

R2

R3

N,N-dimethylcathinone (36)

Me

Me

Me

H

Ethcathinone (37)

Me

Et

H

H

Name

Common Name

R4

4-Methylmethcathinone (27)

Mephedrone

Me

Me

H

4-Me

bk*-PMMA (33)

Methedrone

Me

Me

H

4-OMe

4-Fluoromethcathionone (30)

Flephedrone

Me

Me

H

4-F

Me

Me

H

3-F

3-Fluoromethcathionone (38)
bk*-MDMA (35)

Methylone; MDMC

Me

Me

H

3,4-methylenedioxy

bk*-MDEA (39)

Ethylone

Me

Et

H

3,4-methylenedioxy

bk*-MBDB (40)

Butylone

Et

Me

H

3,4-methylenedioxy

n-Pr

pyrrolidinyl

MDPV (41)

Methylenedioxypyrovalerone

*bk = beta keto.
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3,4-methylenedioxy

Online purchase of mephedrone (27) is claimed to be ‘plant feeders’, ‘bath salts’, and ‘not
for human consumption’ and prosecution as such may be difficult. Mephedrone (27) is most
commonly administered by insufflation (snorting) and oral ingestion.171 Also, because
mephedrone (27) is soluble in water, it is used by rectal administration (dissolved in an enema or
within gelatin capsules), or injected intravenously.171 Mephedrone (27) produces its effects
within a few minutes after being snorted, with the peak effects reached in <30 mins leading to a
rapid comedown.171 Snorted doses of mephedrone (27) range between 25 and 75 mg, with a
threshold dose being 5-15 mg; 90 mg is considered a high dosage.171 Most commonly, oral
dosages are, on average, higher than snorted doses, usually in a range between 150 and 250 mg,
and the onset of action may be of 45 min to 2h.171
Self reported subjective effects of mephedrone (27) have been described, and include
intense stimulation, alertness, euphoria, empathy/feeling of closeness, sociability, talkativeness,
intensification of sensory experiences, moderate sexual arousal and perceptual distortions (only
with higher doses).168,172 There are many unwanted effects associated with mephedrone (27) that
have been reported: adverse effects related to the gastrointestinal system, central nervous system
– neurological and psychiatric, cardiovascular system and renal/urinary excretory system.166
These adverse effects are very similar to those already reported for amphetamine (1),
methamphetamine (2) and MDMA (13), and support a sympathomimetic action by mephedrone
(27).166
The first death related to mephedrone (27) appeared in Sweden in December 2008; only
mephedrone (27) was identified by the toxicological screenings.173 The first mephedrone-related
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death in the USA involved the combined use of mephedrone (27) and heroin.

Based on the

data obtained from the National Programme on Substance Abuse Deaths report, there have been
45 suspected deaths in England associated with mephedrone (27), 12 in Scotland, 1 in Wales, 1
in Northen Ireland and 1 in Guernsey, by the beginning of October 2010.166 Out of these 60
cases, 48 provided positive results for the existence of mephedrone (27), while other cases need
to be further investigated.166
Mephedrone (27), due to its popularity as a legal high, is now a substance controlled by
legislation in the United Kingdom, Germany, Norway, Sweden, The Netherlands, Finland,
Romania, Republic of Ireland, Denmark, Canada and Israel,175 as well as in US. Prevalence of
cathinone (23) derivatives has given rise to both legal and analytical challenges in the
identification of these substances.175 Thus, it is required to develop robust analytical profiling
and validated methods of testing.175 Therefore, recently, many publications have reported the
synthesis of mephedrone (27) and methods for its identification.175-178
It has been found that bath salts contains methylenedioxypyrovalerone (i.e., MDPV; 41) in
addition to mephedrone (27).179 Recently, The New York Times published an article showing the
growing popularity of bath salts in the USA and discussed its danger among people using it.180
Regarding bath salts, Karen E. Simone, director of the Northern New England Poison Center,
says, “If you gave me a list of drugs that I wouldn’t want to touch, this would be at the top.”180
Bath salts have been banned in 28 US states,180 inclunding Virginia. Westphal et al.181 identified
a compound which was seized as a powder in Germany in 2007 as MDPV (41), a pyrovalerone
carrying a methylenedioxy moiety. It has been reported that besides in Germany, MDPV (41) has
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appeared in many countries in Europe and Asia.182 In June 2007 a customs officer in Germany
seized MDPV (41) as a nearly pure substance while investigating a person who was the
addressee of a drug mail shipment from China.181 In mice, MDPV (41) was found to have a
milder effect on the increase of dopamine levels than methamphetamine (2) and MDMA (13),
and showed no significant influence on serotonin levels.183 It has been seen that in locomotor
activity MDPV (41) has a shorter duration of action compared to MDMA (13) and
methamphetamine (2).183 MDPV (41) has gained popularity for claimed sex-enhancing
properties.184 However, in the study of Ojanpera et al.185 the reputation of MDPV (41) as a sex
drug was found less important; rather, a clear stimulation effect induced by MDPV (41) was seen
in some patients. It was assumed that MDPV (41) is taken orally.182 Ojanpera et al.185 reported a
GCMS method for the detection of MDPV (41) in urine together with the stimulants
amphetamine, methamphetamine (2), and MDMA (13). In Japan, Uchiyama et al.186 found seven
designer drugs in fifteen confiscated products, including: MDPV (41), bk-MBDB (40), bkMDEA (39), N-hydroxy-1-(3,4-methylenedioxyphenyl)-2-aminopropane (N-OH MDMA), Nmethyl-1-(4-fluorophenyl)propan-2-amine (N-Me-4-FMP; 30), and 5-methoxy-N-ethyl-Nisopropyltryptamine (5-Meo-EIPT). In the United Kingdom, MDPV (41) was banned in 2010 by
way of a generic definition.187 It has been reported that mephedrone (27), methylone (35) and
MDPV (41) seizures collectively represented over 97% of the synthetic cathinone seizures.188
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Archer189

has

reported

that

internet-based

companies

are

known

to

sell

4-

fluoromethcathinone (flephedrone; 30), the N-methyl analog of 4-fluorocathinone (29), and he
reported a method for the synthesis and identification of various fluoromethcathinones (includes:
2-fluoromethcathinone (42), 3-fluoromethcathinone (38), 4-fluoromethcathinone (30)). There
have been no animal studies reported using flephedrone (30).
Flephedrone (30) is the N-methyl cathinone analog of p-fluoroamphetamine (7). Table 1
shows the invitro potency of p-fluoroamphetamine (7) as a releaser of monoamine
neurotransmitters.34 p-Fluoroamphetamine (7) produced stimulus generalization in rats trained to
discriminate

(+)-amphetamine

fluoromethamphetamine

(28)

from
and

saline.25

There

p-fluorocathinone

is
(29)

little
which

known
are,

about

p-

respectively,

methamphetamine and cathinone counterparts of flephedrone (30) but (±)-4-fluorocathinone (29)
failed to produce hypermotor activity in mice.136 In 2003, a series of clandestinely prepared
phenylalkylamines was seized in the federal state of Sachsen-Anhalt (Germany), which
contained 4-fluoroamphetamine (7) as well as 4-fluoromethamphetamine (28).190 It has been
reported that since 2008, larger quantities of drug preparations containing 4-fluoroamphetamine
have been seized in several German federal states and in Switzerland.191
Methedrone (33), the N-methyl analog of 4-methoxycathinone (32), was reported as an
abused substance for the first time in October 2009 and two deaths were partly attributed to
methedrone (33) in Sweden.192,193 Wilkstrom et al.194 reported two deaths related to methedrone
(33) due to its toxic properties and they found that blood concentrations in the two cases are
close to those seen in subjects who abused the drug, suggesting that a rather narrow “therapeutic”
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window exists for methedrone (33). This emphasizes the risks associated in taking this kind of
drug for recreational purposes.194 Methedrone (33) is controled in Sweden and Romania.164
There are no aminal or pharmacological studies on methedrone (33).
Camilleri et al.176 reported the results of chemical analysis of four capsules delivered to the
Royal Adelaide Hospital (Australia), which originated from an Israel-based internet company,
“Neorganics”. They found that capsule 1, which was marketed as “Spirit”, contained 4methylmethcathinone (mephedrone; 27); capsule 2, which was marketed as “Sub Coca 2”,
contained α-phthalimidopropiophenone and 2-fluoromethcathinone (42); capsule 3 and capsule
4, which were marketed as “Neo dove” and “Sub Coca”, respectively, both contained caffeine, 4methylmethcathinone

(mephedrone,

27),

N-ethylcathinone

(37)

and

α-

phthalimidopropiophenone.176 Jankovics et al.195 developed a “screening method” to provide a
preferably simple and fast analytical procedure for the detection of methcathinone-derived
designer drugs, including: mephedrone (27), methedrone (33), flephedrone (30), MDPV (37),
methylone (MDMC; 35), butylone (i.e., bk-MBDB; 40) and 4-methylethcathinone (4-MEC).
Methedrone (33) is the N-methyl cathinone analog of 4-methoxyamphetamine (PMA, 11).
In two separate studies, it has been observed that PMA (11) results in amphetamine stimulus
generalization, but is less potent than amphetamine.28,29 Table 1 shows the invitro monoamine
transporter release potency of PMA (11). PMMA (p-methoxymethamphetamine, 31), a
methamphetamine counterpart of methedrone, failed to produce stimulus generalization in rats
trained to discriminate (+)-amphetamine from saline.30 However, PMMA (31) produced
complete stimulus generalization in rats trained to discriminate MDMA (13) from saline and was
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three times more potent than MDMA (13).196 PMA (11) produced partial stimulus generalization
in rats trained to discriminate PMMA (31) from saline.197 Shulgin has called PMMA (31)
“DOONE”.198 PMA (11) has been found a potent hallucinogen.199 (+)-PMA and (-)-PMA failed
to produce stimulus generalization in rats trained to discriminate (+)-amphetamine from saline,
however (-)-PMA, but not (+)-PMA, substituted for PMMA (31) in PMMA (31) trained rats.200
PMA (11) is classified as a Schedule I controlled substance.201 (+)-PMMA completely, while (-)PMMA partially, substituted for (±)-PMMA (31) in rats trained to discriminate (±)-PMMA from
saline.202 Table 6 shows the potency of (+)-PMMA and (-)-PMMA as releasers of
neurotrasmitters.203 It has been reported that PMA (11) produces little locomotor stimulation in
mice at doses below 30 mg/kg and that PMMA (31) looks even less potent than PMA (11) at
doses of up to 30 mg/kg.30 PMA (11), compared to (+)-amphetamine, is more effective in
increasing the release and blocking the uptake of 3H-serotonin, while less effective in increasing
the release and blocking the uptake of 3H-norepinephrine and 3H-dopamine.204 PMA (11) has
been used illicitly in Australia since 1994 and later became popular at rave parties in the US.36 In
2000, three fatal cases were reported involving PMA (11) and PMMA (31) abuse in Denmark.205
4-Methoxycathinone (32), which is the cathinone counterpart of methedrone (33), failed to
produce stimulus generalization in rats trained to discriminate cathinone from saline.206 It has
been also reported that 4-methoxycathinone (32) failed to produce locomotor activity in mice.136
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Table 6. In vitro potency as releasers of neurotransmitters.203
Drug

S(+)PMMA

Release
NET
EC50 nM
147

Release
DAT
EC50 nM
1000

Release
SERT
EC50 nM
41

R(-)PMMA

1600

> 14000

134

In conclusion, β-keto amphetamines, including: mephedrone (27), methedrone (33),
flephedrone (30), MDPV (41), methylone (MDMC; 35) and many others, have recently become
popular on the illicit drug market and, as discussed above, there are many reports regarding their
abuse. Furthermore, although cathinone (23) and methcathinone (24) are controlled substances,
their analogs are not. These drugs are a growing threat for society they financially, socially, as
well as producing detrimental effects on health among their users. There is essentially nothing
known about their pharmacology (except cathinone (23) and methcathinone (24)). Based on the
structural similarity of these drugs to cathinone (23) and methcathinone (24), one might assume
that their pharmacology and mechanism of action could be similar to cathinone (23) and
methcathinone (24), but little is known based on current scientific data. One of the difficulties in
studying these drugs is to obtain them in pure form. Bath salts (containing primarily methedrone
(27) and MDPV (41)), as mentioned above, is recently gaining more and more in popularity on
the illicit market. Certainly, based on increasing interest of these cathinone derivatives among
abusers, there is a need for more research to determine how these drugs are producing their effect
and also a need for validated techniques to screen potential candidates related to the cathinones
which might become a future threat.
53

II. Specific Aims

The overall goal of the present project is to synthesize and initiate an examination of the
mechanism(s) of action of a new class of abused substances known as “cathinones”, “synthetic
cathinones”, or “β-keto amphetamines” and, more specifically, the constituents of “bath salts”
and several structurally related agents. These substances represent a relatively new and fastgrowing class of designer drugs (Table 5). Although the first members of this class, cathinone
(23) and methcathinone (24), were identified more than 30 years ago (see Introduction), it is only
within the last few years that they have been acknowledged as representing the first members of
an entire class of agents. These agents are, structurally, β-keto analogs of amphetamine and
might be referred to as “amphetamones”. That is, the amphetamone counterpart of amphetamine
(1) is cathinone (23), whereas that of methamphetamine is methcathinone (24). Although
cathinone and methcathinone are Schedule 1 substances,207 analogs of these agents are
essentially unregulated. It might be noted that certain states have controlled various specific βketo amphetamines, but they have not been regulated at the federal level. (“Bath salts”, itself,
was placed in US Schedule 1208 only after the synthetic and pharmacological studies described
below were completed.)
“Bath salts” is a combination of two cathinone or ‘synthetic cathinone’ analogs:
mephedrone (27) and MDPV (41). Mephedrone is the amphetamone analog of N-methyl pTAP
(i.e., 25). MDPV (41) is a co-constituent of “bath salts”; one explanation for its presence in the
mixture is that it is a contaminant (i.e., a synthetic precursor of mephedrone).
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However, it is difficult (if not impossible) to understand how mephedrone could be prepared
from MDPV, or how MDPV could be a by-product of mephedrone synthesis. Another possibility
is that MDPV is simply a “filler”. But, why go to the trouble of preparing this compound when
much simpler “fillers” (e.g. lactose) could be used. A third possibility is that MDPV is
behaviorally active. Yet, being a tertiary amine with a homologated α-methyl group, current
amphetamine-like SAR would suggest that this compound should be inactive. So, why is MDPV
present in the “bath salts” mixture?
One, relatively obscure, study found that a 20 mg/kg dose of MDPV (41) (i.e., the only dose
examined) increased the locomotor activity of mice.183 The same study also found that MDPV
can increase striatal levels of DA.183 Hence, the possibility exists that MDPV (41) might act at
the level of the dopamine transporter. This needs to be further examined. Nevertheless, although
this is a clue that MDPV might be psychoactive, there is certainly no reason to suspect (from a
structure-activity perspective) that MDPV would ever become a component of a widely used
drug of abuse (i.e., ‘bath salts’). Given its seemingly low potency (i.e., it was evaluated at a dose
of 10 times that of methamphetamine),183 MDPV might not seem attractive (relative to the
potency of other central stimulants) for distribution. Certainly, then, there was no obvious reason
why it should be included with mephedrone as a component of bath salts.
Flephedrone (30) is the N-methyl cathinone analog of p-fluoroamphetamine (7). Recently,
flephedrone abuse has been on an increase190,191 and, because it is an analog of methcathinone,
an agent that acts at the dopamine transporter, it is essential to examine its activity at the
dopamine transporter as well.
Methedrone (33) is the N-methyl analog of 4-methoxycathinone (32). There are some
deaths reported related to abuse of methedrone (see Introduction). Methedrone is the N-methyl
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cathinone analog of the Schedule 1 drug 4-methoxyamphetamine (PMA, 11).201 Methedrone is
also the methcathinone analog of p-methoxymethamphetamine (PMMA, 31), which is also a
drug of abuse. Based on this knowledge regarding methedrone, it is important to study its
mechanism of action.
A major goal of the present investigation will be to prepare mephedrone (27), methedrone
(33), and flephedrone (30) so that their actions at the hDAT can be evaluated and compared with
that of methamphetamine (2) and methcathinone (24). Structurally-related amphetamine and
cathinone analogs (see Figure 3) not currently on-hand will also be synthesized.
A related goal is to prepare at least one example of the optical isomers of a cathinone and/or
methcathinone analog to determine the effect of stereochemistry.
Other proposed synthetic targets are (±)amphetamine (1), the individual optical isomers of
3,4-dichloroamphetamine (43), and S(+)-N-ethylamphetamine.

Krasnodara Cameron, a graduate student in the De Felice laboratory, obtained the response
as shown in Figure 4 using different combinations of (+)-amphetamine and (-)-amphetamine.
The response curve appears to show an anomaly for the 5:5 mixture (i.e., the ‘synthetic’
racemate). To resolve the problem, authentic (±)-amphetamine (1) will be synthesized and
evaluated.
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Figure 4. Response (normalized current) curve of isomers of amphetamine (1) at different ratios
generated at the hDAT expressed in frog oocytes.

The individual optical isomers of 3,4-dichloroamphetamine will be synthesized as a
precursor for its eventual reduction with tritium gas to obtain tritiated isomers of amphetamine.
These will be utilized for studying transport mechanisms at the DAT.
One of the cathinones reported in Table 5 is ethcathinone (37), which is the N-ethyl
homolog of cathinone (23). To determine whether the amphetamine analog of ethcathinone (37)
acts at the DAT, S(+)-N-ethylamphetamine (S(+)44) will be synthesized.
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In summary, then, the specific aims of the present study are:
a) To prepare mephedrone (27), methedrone (33), and flephedrone (30), compounds identified
in what have been termed ‘bath salts’ for examination at the DAT
b) To prepare, where necessary, amphetamine and/or methamphetamine analogs related to the
above compounds for comparison with their cathinone or methcathinone counterparts at the
DAT. Specifically, the following compounds are considered:

Compounds 7, 11, and 31 are already on-hand, so compounds 16, 25, and 28 will be synthesized.
c) To prepare a pair of optical isomers of a cathinone or methcathinone analogs for
examination at the DAT to determine the role of stereochemistry.
d) To examine the effect of MDPV at the DAT.
e) To prepare an authentic sample of racemic amphetamine (1), the individual optical isomers
of its 3,4-dichloro counterpart (i.e., 43), and S(+)-N-ethylamphetamine (S(+)44).
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IV. Results and Discussion

A.

SYNTHESIS
The various amphetamine and cathinone analogs required for this study were prepared in

our laboratory. For example, the synthesis of mephedrone (27), methedrone (33) and flephedrone
(30) are shown in Scheme 1.

Scheme 1. a: Br2, CH2Cl2, N2, rt; b: i) MeNH2 (in 33% ethanol), absolute EtOH 0 °C; ii)
concentrated HCl
Compounds 27, 33, and 30 were prepared based on published procedures for similar
compounds.209,210

4-Methylpropiophenone

(45),

4-methoxypropiophenone

(46)

and

4-

fluoropropiophenone (47) were dissolved in CH2Cl2 and allowed to react with bromine
individually to afford white solid compounds 48, 49, and 50, respectively. These intermediates
were treated individually with MeNH2 at 0 °C in absolute EtOH to afford the free base of
compounds 27, 33, and 30 which, upon treatment with concentrated HCl, resulted in their
hydrochloride salts. The melting points of compounds 27, 33, and 30 were consistants with their
reported melting points.167,211,212
59

p-Methylamphetamine (16) was prepared following a published procedure for a similar
compound (i.e., (±)-amphetamine) (Scheme 2).213,214

Scheme 2. a: CH3CH2NO2, n-butylamine, reflux; b: i) LiAlH4, reflux; ii) HCl gas
p-Methylbenzaldehyde (51) was allowed to react with nitroethane in the presence of nbutylamine under reflux for 9 h to afford yellow crystals of p-methylnitrostyrene (52).
Compound 52 was reduced with LiAlH4 to give the free base of p-methylamphetamine (16)
which upon treatment with HCl gas, resulted in the hydrochloride salt 16. The melting point of
compound 16 was consistant with the literature melting point for this compound.215
p-Methylmethamphetamine (25) was prepared from p-methylamphetamine (16) as shown in
Scheme 3 based on the reported procedure for a similar compound (i.e., (R)-2-methylamino-1phenylpropane).216

Scheme 3. a: ClCOOCH3, K2CO3, rt; b: i) LiAlH4, reflux; ii) aqueous HBr
p-Methylamphetamine (16) was treated with methyl chloroformate in the presence of
K2CO3 for 1 h at room temperature to give 53. Compound 53 was reduced with LiAlH4 to afford
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p-methylmethamphetamine as the free base, which was treated with aqueous HBr to afford the
hydrobromide salt 25. The melting point of compound 25 (mp = 125-128 °C) was not consistant
with that in the literature (mp = 159 °C);217 therefore, the product was further characterized by
elemental microanalysis for C, H, and N, and instrumental analysis which supported the structure
of compound 25.
p-Fluoromethamphetamine (28) was prepared based on a reported procedure by Fotsch et
al. (Scheme 4).218

Scheme 4. a: i) CH3NH2·HCl, NaBH4, Ti(IV)[OCH(CH3)2]4; ii) HCl gas
4-Fluorophenylacetone (54) was reacted with methylamine HCl and titanium (IV)
isopropoxide in the presence of trimethylamine for 3 h at room temperature to afford the free
base of p-fluoromethamphetamine (28). The free base was treated with HCl gas to obtain the
hydrochloride salt 28. The final product, 28, was characterized by elemental microanalysis for C,
H, and N.
Attempts were made to prepare the optical isomers of mephedrone (27). One of the routes,
shown below in Scheme 5, was based on a published procedure for a similar compound (i.e., (S)2-amino-1-(4-methylphenyl)-1-propanone).219
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Scheme 5. a: oxalyl chloride: b: AlCl3; c: CF3COOH
Compound 56 was prepared by treating Boc-N-methyl-D-alanine (55) with oxalyl chloride.
Then compound 56 was reacted with toluene using a Lewis acid, AlCl3, as catalyst in an attempt
to obtain compound 57, but this reaction did not work. A possible explanation for this might be
that in the presence of the Lewis acid the Boc-protecting group is not stable. So, a different route
was explored with a different protecting group to overcome this problem. This route (Scheme 6)
was based on the published procedure for a similar compound (i.e., (S)-2-amino-1-(4methylphenyl)-1-propanone).219
Compound 59 was prepared by treating N-methyl-L-alanine (58) with ethyl trifluoroacetate
in the presence of 1,1,3,3-tetramethylguanidine. Compound 59 was treated with oxalyl chloride
to obtain compound 60, which upon treatment with toluene in the presence of AlCl3 should give
compound 61. But, unfortunately, this reaction did not work. This result was not expected and no
possible explanation can be offered.
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Scheme 6. a: CF3COOC2H5, 1,1,3,3-tetramethylguanidine; b: oxalyl chloride; c: AlCl3
Another attempt is shown in Scheme 7.

Scheme 7. a: CF3COOC2H5, 1,1,3,3-tetramethylguanidine; b: oxalyl chloride; c: AlCl3; d:
K2CO3, CH3I
Compound 63 was prepared by treating D-alanine with ethyl trifluoroacetate in the presence
of 1,1,3,3-tetramethylguanidine.219 The compound 64 was made by reacting compound 63 with
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oxalyl chloride.219 Friedel Crafts acylation was accomplished using AlCl3 to afford compound 65
from compound 64 and toluene.219 Then compound 65 was treated with CH3I in the presence of
K2CO3 to obtain compound 66.220 Here, optical activity was lost and compound 66 was obtained
as a racemic mixture. A possible explanation is due to the presence of base the carbonyl group in
compound 65 undergoes tautomerism which results in the racemic product.
A totally different route to prepare the isomers of mephedrone (27) is shown in Scheme 8.

Scheme 8. a: SOCl2; b: AlCl3; c: CH3NH2
Compound 68 was prepared by treating S(-)-2-bromopropionic acid with thionyl chloride.221
Compound 48 was then obtained by reacting compound 68 with toluene in the presence of
AlCl3.219 Compound 48 was not optically active. A possible explanation for this racemization is
the presence of the Lewis acid which promotes tautomerism which ultimately gives rise to
racemic product.
Because many of the problems encountered in the above reactions seem to be related to the
Friedel-Crafts acylation step, an attempt was made to prepare a known compound using a
published procedure. Specifically, we focused on the preparation of optical isomers of pmethylcathinone (26) using a published route.219
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Scheme 9. a: CF3COOC2H5, 1,1,3,3-tetramethylguanidine; b: oxalyl chloride; c: AlCl3; d:
concentrated HCl, i-PrOH
Compound 65 was prepared as mentioned in Scheme 7. Compound 65 was treated with
concentrated HCl and i-PrOH to give one of the optical isomer of p-methylcathinone (i.e.
R(+)26). The other isomer of p-methylcathinone (i.e. S(-)26) was obtained by the same synthetic
scheme. Both optical isomers were characterized by microanalysis of C, H, and N, which
supported the structure of the products, and optical rotations for the isomers were comparable
with literature rotations.
After attempting many routes to obtain optical isomers of mephedrone (27), finally, we
succeeded in making the optical isomers of p-methylcathinone (26) which are cathinone analogs
of mephedrone (27, p-methylmethcathinone).
S(+)-N-Ethylamphetamine (S(+)44) was prepared based on a published procedure (Scheme
10).222
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Scheme 10. a: (AcO)2O, Na2CO3; b: i)LiAlH4, THF, reflux; ii) HCl gas
Compound 69 was obtained by treatment of S(+)-amphetamine (S(+)1) with acetic
anhydride in the presence of Na2CO3. Compound 69 was reduced with LiAlH4 in THF to give
S(+)-N-ethylamphetamine which upon treatment with HCl gas gave a yellow solid. The melting
point of the compound S(+)44 matches the reported melting point,223 and the optical rotation is
consistent with the literature.224
Racemic amphetamine (1) was prepared by same procedure mentioned in Scheme 2. The
only change was that benzaldehyde was used instead of p-tolualdehyde (Scheme 11).213,214

Scheme 11. a: CH3CH2NO2, n-butylamine, reflux; b: i) LiAlH4, reflux; ii) HCl gas
Racemic amphetamine (1) was obtained as its free base which upon treatment with HCl gas
gave a white solid. The melting point of racemic amphetamine hydrochloride (1) matched the
literature melting point.225
Attempted preparation of the individual optical isomers of 3,4-dichloroamphetamine, using
the same procedure as in Scheme 7,219 is shown in Scheme 12.
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Scheme 12. a: CF3COOC2H5, 1,1,3,3-tetramethylguanidine; b: oxalyl chloride; c: AlCl3
Compound 64 was prepared as described in Scheme 7. Compound 64 was treated with 3,4dichlorobenzene in the presence of AlCl3 to give compound 72. The reaction gave a product, but
the yield was very low. Compound 72 was characterized by microanalysis of C, H, and N, which
supported its structure.
The low yield may be due to the presence of two halogen groups on the benzene ring which
might deactivate the aromatic ring to acylation.
As the above route was not very efficient, it was decided to synthesize racemic 3,4dichloroamphetamine (43) using the same route shown in Scheme 2,213,214 and then resolve it.

Scheme 13. a: CH3CH2NO2, n-butylamine, reflux; b: LiAlH4, reflux
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The only difference in Scheme 2 and Scheme 13 is that Scheme 2 uses pmethybenzaldehyde as starting material while 3,4-dichlorobenzaldehyde was used as staring
material in Scheme 13. The melting point of 3,4-dichloroamphetamine matched the literature
melting point. 3,4-Dichloroamphetamine (43) was reacted with N-acetyl-L-leucine to obtain a
salt.226 The salt was recrystallized multiple times from H2O.226 But, unfortunately, the isomers of
3,4-dichloroamphetamine were not obtained. Resolution of 3,4-dichloroamphetamine (43) with
(-)-O-O’-dibenzoyl-L-tartaric acid,227 using MeOH as solvent was also not useful. Synthesis of
the isomers was abandoned.

B.

ELECTROPHYSIOLOGY:
Xenopus laevis oocytes were surgically harvested and injected with hDAT

mRNA.228,229 Then, the injected oocytes were incubated for a period of 4-6 days in an incubation
solution. Oocytes were held at -60 mV in a two-electrode voltage clamp system for all assays,
and maintained in a bath with standard recording solution (120 mM NaCl, 5.4 mM K gluconate,
1.2 mM Ca gluconate, 15 mL of 0.5 M HEPES). All solutions were prepared in standard
recording solutions and perfused over the oocytes using a gravity-fed perfusion system once a
stable baseline was obtained. (Note: Electrophysiological studies were done by Krasnodara
Cameron, a graduate student in Dr. De Felice Laboratory)
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Figure 5. Dose-response curve for S(-)-methcathinone (S(-)24).
Figure 5 shows the dose-response curve of S(-)-methcathinone (S(-)24). Various data points
were obtained by exposing hDAT-expressing oocytes to different concentrations of the S(-)methcathinone (S(-)24) and measuring the peak current. The EC50 value for S(-)-methcathinone
(S(-)24) was determined to be 0.14 μM. The same method applied to S(+)-methamphetamine
(S(+)2) provided an EC50 value of 0.56 (±0.08) μM (data not shown). These studies confirmed
previous findings,147,230 using different methods, that S(-)-methcathinone is more potent than
S(+)-methamphetamine. S(-)-Methcathinone (S(-)24) and S(+)-methamphetamine (S(+)2) will be
used here as standards for comparing all compounds proposed in the Specific Aims.
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Figure 6. Dose-response curve for racemic mephedrone (27).
A dose-response curve was obtained for (±)-mephedrone (27) (Figure 6) and it was
determined that the EC50 of (±)-mephedrone (27) is 0.75 μM. It shows that (±)-mephedrone (27)
has slightly lower potency (EC50=0.75 μM) than S(+)-methamphetamine (EC50=0.56 μM) and
almost 6-fold lower potency than S(-)-methcathinone (EC50=0.14 μM). Although considering its
EC50 value is for the racemate, the S-enantiomer of mephedrone might have a potency higher
than that of S(+)-methamphetamine (S(+)2). This remains to be determined. (±)-Mephedrone
(27) showed notably lower efficacy (41%) than S(+)-methamphetamine (S(+)2)(102%) but it
showed comparable efficacy to S(-)-methcathinone (S(-)24)(56%).
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Figure 7. Current generated in hDAT by application of drugs (10 μM) at -60 mV. All traces
were normalized to the peak size of S(-)MCAT (S(-)24) and were in the range of 10-20 nA. A.
S(+)-methamphetamine (S(+)2); B. S(-)-methcathinone (S(-)24); C. (±)-mephedrone (27).

As shown in Figure 7, (±)-mephedrone (27) as well as S(-)-methcathinone (S(-)24)
generated depolarizing currents with a sustained leak current (also called a ‘shelf’) that persisted
even after the drug was removed. Multiple experiments showed that the size of shelf current was
proportional to the time of exposure and the concentration of the drug (data not shown). It was
found that the persistent depolarizing current caused by (±)-mephedrone (27) was proportionally
larger than the shelf current induced by S(+)-methamphetamine (S(+)2) but less pronounced than
in the case of S(-)-methcathinone (S(-)24). The similarity of the electrophysiological signature of
(±)-mephedrone (27) to that of S(+)-methamphetamine (S(+)2) suggests that (±)-mephedrone
(27) shares dopamine-like releasing properties similar to S(+)-methamphetamine (S(+)2).
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As mentioned earlier (see Introduction), mephedrone (27) and MDPV (41) are constituents
of “Bath salts”. It is worth discussing the electrophysiological results of MDPV (41) here. (Note:
MDPV (41) was synthesized by Dr. R. Kolanos, in Dr. Glennon’s lab). It was found that (±)MDPV (41) failed to produce a depolarizing effect similar to that of (±)-mephedrone (27).
Unlike, (±)-mephedrone (27), (±)-MDPV (41) produced a hyperpolarizing current at hDAT
similar to that produced by cocaine.

Figure 8. Blockade of hDAT-mediated currents at -60 mV. A) S(+)-amphetamine (S(+)1) is
blocked by cocaine; B) (±)-mephedrone (27) blocked by cocaine; C) (±)-mephedrone blocked by
(±)-MDPV (41). Traces were normalized to the peak size of S(-)-methcathinone (Figure 6) and
were in the range of 10-20 nA.

The persistent shelf current produced by (±)-mephedrone (27) at hDAT is reversed,
similarly to the S(+)-amphetamine (S(+)1) shelf reversal, by cocaine (a hDAT blocker) (Figure
8). The current generated by (±)-mephedrone (27) was also blocked by (±)-MDPV (41),
suggesting that the (±)-MDPV (41), although structurally similar to other cathinones and very
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different from cocaine, might represent a new class of cocaine-like hDAT blocker. Preliminary
data indicated that (±)-MDPV (41) blocks hDAT-mediated current for a significantly longer time
than cocaine. This action might be responsible for the “strong addicting” properties of (±)MDPV (41) reported online by users.

Figure 9. Dose-response curves for S(+)-methamphetamine (S(+)2), S(-)-methcathinone (S()24), (±)-mephedrone (27) and (±)-MDPV (41) in hDAT at -60 mV. In the case of (±)-MDPV
(41) each drug concentration was applied in the presence of dopamine (5 μM).

Figure 9 shows the dose-response curves for S(+)-methamphetamine (S(+)2), S(-)methcathinone (S(-)24), (±)-mephedrone (27) and (±)-MDPV (41). As mentioned earlier, it can
be seen in Figure 9 that (±)-mephedrone (27) has notably lower efficacy (41%) than S(+)methamphetamine (S(+)2)(102%), but it has comparable efficacy to S(-)-methcathinone (S(73

)24)(56%). Figure 9 also shows that (±)-MDPV (41) blocking the dopamine produced
depolarization as mentioned earlier.
To conclude, the studies showed that structurally related synthetic cathinones can have
dissimilar biophysical signatures depending on the feature added to the β-keto amphetamine
template. “Bath salts” contains both (±)-mephedrone (27) and (±)-MDPV (41) as major
ingredients. (±)-Mephedrone (27) has the biophysical signature of a dopamine releasing agent
just like S(+)-methamphetamine (S(+)2) whereas the other synthetic cathinone, (±)-MDPV (41),
appears to behave as a cocaine-like dopamine reuptake inhibitor. The combination of these two
mechanisms may account for the severe behavioral toxicity of “bath salts” (see Introduction).
“Bath salts” are relatively new products to the drug abuse market, hence there is limited
information about their mechanism of action. The above-mentioned results might be useful in
prediction of releasing or blocking properties of existing and novel psychoactive drugs as well as
forecasting the action of next-generation drugs with abuse potential.
Just as with (±)-mephedrone (27), the EC50 of (±)-flephedrone (30) was obtained (1.10 μM).
Studies showed that flephedrone (data not shown) is half as potent as S(-)-methamphetamine
(EC50=0.56 μM) and 10-fold less potent than S(-)-methcathinone (EC50=0.14 μM). Flephedrone
(30) was found to produce 65% effect relative to DA. However, the similarity of the
electrophysiological signature of (±)-flephedrone (30) and S(+)-methamphetamine (S(+)2)
suggested that (±)-flephedrone (30) shares dopamine-like releasing properties similar to S(+)methamphetamine (S(+)2).
Methedrone (33) and other amphetamine, methamphetamine, and cathinone analogs
described in the Specific Aims (compounds: 7, 11, 16, 25, 28, and 31) are currently under
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investigation. The pair of optical isomers of p-methylcathinone (i.e. S(-)23, and R(+)23) and
S(+)-N-ethylamphetamine (S(+)44) are also under investigation.

+/- AMPH

180

Normalized Current

160
140
120
100
ACTUAL- RACEMATE

80

ACTUAL MIX

60
0

+ AMPH
- AMPH

1

0
10

2

3

2
8

5
5

4

8
2

5

10
0

6

Figure 10. Response (normalized current) curve of isomers of amphetamine (1) at different
ratios compared with the response curve of racemic amphetamine (1).
As mentioned in the Specific Aims, the De Felice lab obtained the response curves as
shown in Figure 4 using different combinations of S(+)-amphetamine (S(+)1) and R(-)amphetamine (R(-)1). It appears that an equal mixture of the two isomers produced less of an
effect than either an 8:2 mixture or a 2:8 mixture. This seemingly aberrant response might be the
result of weighing error, or a problem associated with the optical purity of one of the isomers.
(±)-Amphetamine (1) was synthesized and evaluated to resolve the problem. The experiment
shown as Figure 4 was repeated, but racemic amphetamine (1) was used in place of the 5:5
mixture (Figure 10). Figure 10 shows that, in fact, the result in Figure 4 is correct and that both
the actual racemate of amphetamine and the mixture of two isomers gave the same results
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(within experimental error). But, the question now is why the response of racemate amphetamine
is less than that of the 8:2 or 2:8 mixtures. Further investigation is required to properly address
this issue.
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V. Conclusion

The most common constituents of ‘bath salts’, mephedrone (27) and MDPV (41), were
prepared for electrophysiological examination at the hDAT. Methedrone (33) and flephedrone
(30), which might sometimes appear (amongst other agents) in the ‘bath salts’ combination, were
also prepared for evaluation. Amphetamine analogs (i.e., p-methylamphetamine (25), and S(+)N-ethylamphetamine

(S(+)44)),

and

several

methamphetamine

analogs

(i.e.,

p-

methylmethamphetamine (25), and p-fluorometh- amphetamine (28)) were synthesized for
electrophysiological comparison. Optical isomers of p-methylcathinone (26), which is the Ndesmethyl counterpart of mephedrone (27, i.e., p-methylmethcathinone), were synthesized.
Racemic amphetamine, although well known but not readily available, was synthesized. All
compounds were synthesized for examination at hDAT.
‘Bath salts’ contains mephedrone (27) and MDPV (41) (see Introduction) as its most
common constituents; sometimes, other constituents have been identified. Mephedrone was
prepared and examined at the hDAT. (±)-Mephedrone (27; EC50 = 0.75 μM) was found to be
slightly lower in potency than S(+)-methamphetamine (EC50 = 0.56 μM), and almost 6-fold lower
in potency than S(-)-methcathinone (EC50 = 0.14 μM). While (±)-mephedrone (27) displayed
notably lower efficacy (41%) than S(+)-methamphetamine (S(+)2; 102% relative to DA), it
showed comparable efficacy to S(-)-methcathinone (S(-)24; 56%). (±)-Mephedrone (27)
produced an electrophysiological signature similar to that of S(+)-methamphetamine
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(S(+)2) suggesting that (±)-mephedrone (27) shares the dopamine-like releasing properties of
S(+)-methamphetamine (S(+)2). Unlike, (±)-mephedrone (27), (±)-MDPV (41) produced a
hyperpolarizing current at hDAT similar to that produced by cocaine.
The EC50 value of (±)-flephedrone (30) was determined to be 1.1 μM. It was found that (±)flephedrone (30) is half as potent as S(-)-methamphetamine (EC50 = 0.56 μM) and 10-fold less
potent than S(-)-methcathinone (EC50 = 0.14 μM). As with (±)-mephedrone (27), (±)-flephedrone
(30) produced an electrophysiological signature similar to S(+)-methamphetamine (S(+)2)
suggesting that (±)-flephedrone (30) shares dopamine-like releasing properties of S(+)methamphetamine (S(+)2).
Methedrone (33), and other amphetamine, methamphetamine, and cathinone analogs
described in the Specific Aims (compounds: 7, 11, 16, 25, 28, and 31) are currently under
investigation. The pair of optical isomers of p-methylcathinone (i.e. S(-)23, and R(+)23) and
S(+)-N-ethylamphetamine (S(+)44) are also under investigation. Preliminary data (data not
shown) already suggest that methedrone (33) is a dopamine-like releasing agent.
It was found that both racemic amphetamine (1) and the 5:5 mixture of the two individual
optical isomers of amphetamine produce a response less than that of the 8:2 or 2:8 mixture of the
two individual isomers. A possible explanation would be that the R(-)-amphetamine (R(-)1)
might be competitively inhibiting the effect of S(+)-amphetamine (S(+)1) at certain
concentrations. But, further investigation is required to properly address this issue.

The current studies provide the first information about the two major constituents of ‘bath salts’
on the hDAT expressed in Xenopus oocytes and set the stage for future investigations.
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VI. Experimental

A. SYNTHESIS
Melting points were taken on a Thomas-Hoover melting point apparatus in glass capillary
tubes and are uncorrected. 1H NMR spectra were recorded with a Varian EM-390 spectrometer
with tetramethylsilane (TMS) as an internal standard. Peak positions are given in parts per
million (δ). Infrared spectra were obtained on a Nicolet iS10 FT-IR spectrometer. Optical
rotations were measured on a Jasco DIP-1000 digital polarimeter. Microanalyses were performed
by Atlantic Microlab Inc. (Norcross, GA) for the indicated elements and results are within 0.4%
of calculated values. Chromatographic separations were performed on silica gel columns (Silica
Gel 60, 220-440 mesh, Sigma-Aldrich). Reactions were monitored by thin-layer chromatography
(TLC) on silica gel GHLF plates (250 μ, 2.5 x 10 cm; Analtech Inc., Newark, DE).

Amphetamine Hydrochloride (1). Compound 1 was prepared according to a literature
procedure.214 A solution of 1-phenyl-2-nitropropene (71, 1.5 g, 9.2 mmol) in anhydrous THF (9
mL) was added in a dropwise manner to a suspension of LiAlH4 (1.5 g, 40.4 mmol) in Et2O at 0
°C (ice-bath). After completion of addition, the mixture was heated at reflux for 2 h and then
quenched at 0 °C by the dropwise addition of absolute EtOH (1.5 mL), H2O (1.5 mL), and 15%
aqueous NaOH (1.5 mL). The mixture was filtered and the filtrate was dried (Na2SO4). The
solvent was removed under reduced pressure to give an oily residue. The residue was dissolved
in absolute EtOH and saturated with HCl gas to afford a
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yellow solid. Recrystallization from absolute EtOH/anhydrous Et2O gave 0.3 g (22%) of 1 as
white crystals: mp 147-150 °C (lit.225 mp 147-149 °C); 1H-NMR (DMSO-d6: salt) δ 1.1(d, J =
6.5 Hz, 3H, CH3), 2.65 (dd, J = 13.2, 9.2 Hz, 1H, CH2), 3.05 (dd, J = 13.2, 5.0, 1H, CH2), 3.353.40 (m, 1H, CH), 7.22-7.26 (m, 3H, ArH), 7.33 (t, J = 7.2 Hz, 2H, ArH), 8.17 (br s, 3H, NH3+).
1-(4-Methylphenyl)-2-aminopropane Hydrochloride (16; p-Methylamphetamine HCl).
Compound 16 was prepared using a literature procedure for a similar compound.214 1-(4Methylphenyl)-2-nitropropene (52, 1.0 g, 5.6 mmol) in anhydrous THF (6 mL) was added in a
dropwise manner to a stirred suspension of LiAlH4 (0.9 g, 24.8 mmol) in Et2O (14 mL) at 0 °C
(ice-bath). After completion of the addition, the mixture was heated at reflux for 2 h and then
quenched at 0 °C by the dropwise addition of absolute EtOH (0.9 mL), H2O (0.9 mL), and 15%
aqueous NaOH (0.9 mL). The mixture was filtered and the filtrate was dried (Na2SO4). The
solvent was removed under reduced pressure to give an oily residue which was dissolved in
absolute EtOH and saturated with HCl gas to afford a yellow solid. Recrystallization from
absolute EtOH gave 0.3 g (22%) of 16 as white crystals: mp 157-159 °C (lit.215 mp 158-159 °C);
1

H-NMR (DMSO-d6: salt) δ 1.09 (d, J = 6.5 Hz, 3H, CH3), 2.27 (s, 3H, CH3), 2.61 (dd, J = 13.3,

9.2 Hz, 1H, CH2), 2.99 (dd, J = 13.3, 5.0 Hz, 1H, CH2), 3.32-3.37 (m, 1H, CH), 7.10-7.15 (m,
4H, ArH), 8.11 (s, 3H, NH3+).
1-(4-Methylphenyl)-2-methylaminopropane

Hydrobromide

(25;

p-Methylmeth-

amphetamine HBr). Compound 25 was prepared using a literature procedure for a similar
compound.216 N-[1-Methyl-2-(4-methylphenyl)ethyl] methyl carbamate (53, 1.7 g, 8.3 mmol) in
anhydrous THF (5 mL) was added to a cold (0 °C, ice-bath) suspension of LiAlH4 (0.5 g, 12.4
mmol) in anhydrous THF (50 mL) at such a rate that the reaction remained under control. After
addition of the carbamate the reaction mixture was heated at reflux under an N2 atmosphere for 2
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h. The reaction mixture was cooled to 0 °C and quenched with absolute EtOH (0.5 mL), H2O
(0.5 mL) and 15% NaOH (0.5 mL). The mixture was allowed to stir for 30 min, filtered, and the
filtrate was dried (Na2SO4). The solvent was evaporated under reduced pressure to give an oily
residue which was dissolved in absolute EtOH, and aqueous HBr (48%) was added to pH=1. The
aqueous solvent was removed under reduced pressure to afford a white solid. Recrystallization
from absolute EtOH gave 0.9 g (34%) of 25 as white crystals: mp 125-128 °C (lit.217 mp 159
°C); 1H NMR (DMSO-d6) δ 1.07 (d, J = 6.5 Hz, 3H, CH3), 2.28 (s, 3H, CH3), 2.57 (dd, J = 13.1,
9.8 Hz, 1H, CH2), 2.59 (s, 3H, CH3), 3.08 (dd, J = 13.2, 4.3 Hz, 1H, CH2), 3.34-3.45 (m, 1H,
CH), 7.12-7.16 (m, 4H, ArH), 8.48 (br s, 2H, NH2+). Anal. Calcd (C11H17N·HBr) C, 54.11; H,
7.43; N, 5.74. Found: C, 54.21; H, 7.44; N, 5.70.
R(+)-1-(4-Methylphenyl)-2-aminopropan-1-one

Hydrochloride

(R(+)26;

R(+)-p-

Methylcathinone HCl). Compound R(+)26 was prepared using a literature procedure for a
similar compound.219 (R)-N-[2-(4-Methylphenyl)-1-methyl-2-oxoethyl]-2,2,2-trifluoroacetamide
(R(65), 0.5 g, 2 mmol) was dissolved in i-PrOH (44 mL) and concentrated HCl (33 mL). The
resulting solution was then stirred at 40 °C for 12 h. The solvent was evaporated under reduced
pressure, followed by addition of Et2O (15 mL) and i-PrOH (1 mL) to precipitate a white solid.
Recrystallization from absolute EtOH gave 0.05 g (13%) of R(+)26 as white crystals: mp 220225 °C; IR (Diamond): 1682 cm-1 (C=O); 1H NMR (DMSO-d6) δ 1.42 (d, J = 7.2 Hz, 3H, CH3),
1.41 (s, 3H, CH3), 5.04-5.09 (m, 1H, CH), 7.40 (d, J = 8.0 Hz, 2H, ArH), 7.96 (d, J = 8.2 Hz, 2H,
ArH), 8.43 (br s, 3H, NH3+). [α]28D +34 °, c 1, MeOH. Anal. Calcd (C10H13NO·HCl·0.5H2O) C,
57.55; H, 7.07; N, 6.71. Found: C, 57.62; H, 6.88; N, 6.58.
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S(-)-1-(4-Methylphenyl)-2-aminopropan-1-one

Hydrochloride

(S(-)26;

S(-)-p-

Methylcathinone HCl). Compound S(-)26 was prepared according to a literature procedure.219
(S)-N-[2-(4-Methylphenyl)-1-methyl-2-oxoethyl]-2,2,2-trifluoroacetamide
((S)65, 0.5 g, 2 mmol) was dissolved in i-PrOH (44 mL) and concentrated HCl (33 mL). The
resulting solution was then stirred at 40 °C for 12 h. The solvent was evaporated under reduced
pressure, followed by addition of Et2O (15 mL) and i-PrOH (1 mL) to precipitate a white solid.
Recrystallization from absolute EtOH gave 0.1 g (21%) of S(-)26 as white crystals: mp 220-225
°C (lit.219 mp 192-193 °C); IR (Diamond): 1683 cm-1 (C=O); 1H NMR (DMSO-d6) δ 1.42 (d, J =
7.2 Hz, 3H, CH3), 1.41 (s, 3H, CH3), 5.04-5.10 (m, 1H, CH), 7.41 (d, J = 8.0 Hz, 2H, ArH), 7.96
(d, J = 8.2 Hz, 2H, ArH), 8.44 (br s, 3H, NH3+). [α]28D -36.7 °, c 1, MeOH (lit.222 [α]22D -32 °, c
1.06, MeOH).
1-(4-Methylphenyl)-2-methylaminopropan-1-one Hydrochloride (27; Mephedrone HCl).
Compound 27 was prepared using a literature procedure for a similar compound.210 A solution of
2-bromo-(4-methyl)propiophenone (48, 0.5 g, 2.2 mmol) in absolute EtOH (5 mL) was added in
a dropwise manner to a 33% ethanolic solution of MeNH2 at 0 °C (0.2 g, 5.9 mmol) and the
reaction mixture was allowed to stir for 3 h. Cold, concentrated HCl was then added very slowly
along with some finely cracked ice until the mixture became acidic (pH=0). The reaction mixture
was extracted with Et2O (3 x 15 mL) and 48 (0.3 g) was recovered. The aqueous portion was
evaporated under reduced pressure to dryness. The residue was extracted several times with fresh
portions of CHCl3 (3 x 15 mL) and each time the insoluble MeNH2HCl was removed by
filtration. The solvent was evaporated under reduced pressure to give a white solid.
Recrystallization from absolute EtOH gave 0.05 g (27%) of 27 as white crystals: mp 230-232 °C
(lit.167 mp 232 °C); IR (Diamond) cm-1: 1685 (C=O); 1H NMR (DMSO-d6) δ 1.44 (d, J = 7.2 Hz,
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3H, CH3), 1.41 (s, 3H, CH3), 2.59 (s, 3H, CH3), 5.09-5.14 (m, 1H, CH), 7.42 (d, J = 8.0 Hz, 2H,
ArH), 7.94 (d, J = 8.3 Hz, 2H, ArH), 9.28 (br s, 2H, NH2+).
1-(4-Fluorophenyl)-2-methylaminopropane

Hydrochloride

(28;

p-Fluorometh-

amphetamine HCl). Compound 28 was prepared according to a literature procedure.218
Triethylamine (2.0 g, 20 mmol), MeNH2HCl (1.4 g, 20 mmol) and titanium(IV) isopropoxide
(5.7 g, 20 mmol) were added to a solution of 4-fluorophenylacetone (54, 1.5 g, 10 mmol) in
absolute EtOH (15 mL). The solution was allowed to stir for 3 h at room temperature. Then
NaBH4 (0.6 g, 16 mmol) was added to the reaction mixture and stirring was continued for an
additional 3 h. Aqueous NH3 was added and the white precipitate was removed by filtration.
Water was added to the filtrate and the aqueous portion was extracted with CH2Cl2 (3 x 20 mL).
The combined organic portion was washed with 1 N HCl (3 x 10 mL), the aqueous portions were
combined and washed with CH2Cl2 (3 x 10 mL). The aqueous portion was basified (1N NaOH to
bring the pH to 9) and the solution was extracted with CH2Cl2 (3 x 20 mL). The combined
organic portion was dried (Na2SO4) and filtered. The solvent was evaporated under reduced
pressure to give an oily residue which was dissolved in absolute EtOH and saturated with HCl
gas to afford an off-white solid. Recrystallization from absolute EtOH gave 0.4 g (20%) of 28 as
off-white crystals: mp 110-114 °C; 1H NMR (DMSO-d6) δ 1.09 (d, J = 6.5 Hz, 3H, CH3), 2.55
(s, 3H, CH3), 2.66 (dd, J = 13.3, 9.9 Hz, 1H, CH2), 3.16 (dd, J = 13.3, 4.2 Hz, 1H, CH2), 3.323.34 (m, 1H, CH), 7.14-7.19 (m, 2H, ArH), 7.29-7.32 (m, 2H, ArH), 9.03 (br s, 2H, NH2+). Anal.
Calcd (C10H14FN·HCl) C, 58.97; H, 7.42; N, 6.88. Found: C, 58.94; H, 7.36; N, 6.82.
1-(4-Fluorophenyl)-2-methylaminopropan-1-one Hydrochloride (30; Flephedrone HCl).
Compound 30 was prepared using a literature procedure for a similar compound.210 A solution of
2-bromo-(4-fluoro)propiophenone (50, 3.0 g, 13.0 mmol) in absolute EtOH (30 mL) was added
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in a dropwise manner to a 33% ethanolic solution of MeNH2 (1.0 g, 32.5 mmol) at 0 °C (icebath) and the reaction mixture was allowed to stir for 12 h. Cold, concentrated HCl was then
added very slowly along with some finely cracked ice until the mixture was acidic (pH=1). The
reaction mixture was extracted with Et2O (3 x 15 mL). The aqueous portion was evaporated
under reduced pressure to dryness. The residue was washed several times with fresh portions of
CHCl3 (3 x 10 mL). The resultant solid was dissolved in H2O and 1N NaOH was added to the
solution to pH=9. The solution was extracted with CH2Cl2 (3 x 15 mL). The combined organic
portion was dried (Na2SO4) and the solvent was removed under reduced pressure to give a
yellow solid. Recrystallization from absolute EtOH gave 0.05 g (2%) of 30 as yellow crystals:
mp 225-227 °C (lit.212 mp 220-222 °C); IR (Diamond): 1686 cm-1 (C=O); 1H NMR (DMSO-d6) δ
1.45 (d, J = 7.2 Hz, 3H, CH3), 2.59 (s, 3H, CH3), 5.14-5.19 (m, 1H, CH), 7.44-7.48 (m, 2H,
ArH), 8.12-8.16 (m, 2H, ArH), 9.36 (s, 2H, NH2+).
1-(4-Methoxyphenyl)-2-methylaminopropan-1-one Hydrochloride (33; Methedrone HCl).
Compound 33 was prepared using a literature procedure for a similar compound.210 A solution of
2-bromo-(4-methoxy)propiophenone (49, 3.0 g, 12.3 mmol) in absolute EtOH (30 mL) was
added in a dropwise manner to a 33% ethanolic solution of MeNH2 (1.0 g, 30.9 mmol) at 0 °C
(ice-bath) and the reaction mixture was allowed to stir for 12 h. Cold, concentrated HCl was then
added very slowly along with some finely cracked ice until the mixture was acidic (pH=1). The
reaction mixture was extracted with Et2O (3 x 15 mL). The aqueous portion was evaporated
under reduced pressure to dryness. The residue was washed several times with fresh portions of
CHCl3 (3 x 10 mL). The resultant solid was dissolved in H2O and 1N NaOH was added to the
solution to pH=9. This soltution was extracted with CH2Cl2 (3 x 15 mL). The combined organic
portion was dried (Na2SO4) and the solvent was removed under reduced pressure to give a white
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solid. Recrystallization from absolute EtOH gave 1.3 g (47%) of 33 as white crystals: mp 220222 °C (lit.211 mp 216 °C); IR (Diamond): 1678 cm-1 (C=O); 1H NMR (DMSO-d6) δ 1.44 (d, J =
7.1 Hz, 3H, CH3), 2.57 (s, 3H, CH3), 3.88 (s, 3H, CH3), 5.07-5.13 (m, 1H, CH), 7.12 (d, J = 9.0
Hz, 2H, ArH), 8.02 (d, J = 9.0 Hz, 2H, ArH), 9.30 (s, 2H, NH2+).
1-(3,4-Dichlorophenyl)-2-aminopropane Hydrochloride (43; 3,4-Dichloro-amphetamine
HCl). Compound 43 was prepared using a literature procedure for a similar compound.214 1-(3,4Dichlorophenyl)-2-nitropropene (74, 6.1 g, 26.2 mmol) in anhydrous THF (5 mL) was added in a
dropwise manner to a stirred suspension of LiAlH4 (4.4 g, 115.4 mmol) in Et2O (50 mL) at 0 °C
(ice-bath). After completion of the addition, the mixture was heated at reflux for 2 h and then
quenched at 0 °C by the dropwise addition of absolute EtOH (5 mL), H2O (5 mL), and 15%
aqueous NaOH (15 mL). The mixture was filtered and the filtrate was dried (Na2SO4). The
solvent was evaporated under reduced pressure to give an oily residue which was dissolved in
absolute EtOH and saturated with HCl gas to afford a yellow solid. Recrystallization from
absolute EtOH gave 2.7 g (42%) of 43 as white crystals: mp 175-178 °C (lit.231 mp 188-189 °C);
1

H-NMR (DMSO-d6: salt) δ 1.16 (d, J = 6.5 Hz, 3H, CH3), 2.77 (dd, J = 13.5, 8 Hz, 1H, CH2),

3.04 (dd, J = 13.5, 5.9 Hz, 1H, CH2), 3.34-3.46 (m, 1H, CH), 7.29 (dd, J = 8.2, 2 Hz, 1H, ArH),
7.58 (m, 2H, ArH), 8.26 (s, 3H, NH3+).
S(+)-1-Phenyl-2-ethylaminopropane

Hydrochloride

(S(+)44;

S(+)-N-Ethyl-

amphetamineHCl). Compound S(+)44 was prepared according to a literature procedure.222
S(+)-N-(2-Phenyl-1-methylethyl)acetamide (S(+)69, 1.5 g, 8.5 mmol) in anhydrous THF (20 mL)
was added to a cold (0 °C, ice-bath) suspension of LiAlH4 (0.5 g, 12.6 mmol) in anhydrous THF
(8 mL) at such a rate that the reaction remained under control. After addition of amide the
reaction mixture was heated at reflux under an N2 atmosphere for 15 h. The reaction mixture was
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cooled at 0 °C and quenched with H2O (0.5 mL), 15% NaOH (0.5 mL) and H2O (1.4 mL). The
mixture was allowed to stir for 30 min, filtered, and the filtrate was dried (Na2SO4). The solvent
was evaporated under reduced pressure to give an oily residue, which was dissolved in absolute
EtOH and saturated with HCl gas to afford a yellow solid. Recrystallization from absolute
EtOH/anhydrous Et2O gave 0.3 g (18%) of S(+)44 as yellow crystals: mp 147-150 °C (lit.223 mp
141-142 °C); 1H NMR (DMSO-d6) δ 1.09 (d, J = 6.6 Hz, 3H, CH3), 1.24 (t, J = 7.2 Hz, 3H,
CH3), 2.62 (dd, J = 13.1, 10.4 Hz, 1H, CH2), 2.95-3.04 (m, 2H, CH2), 3.23 (dd, J = 13.1, 3.8 Hz,
1H, CH2), 3.35-3.40 (m, 1H, CH), 7.24-7.27 (m, 3H, ArH), 7.34 (t, J = 7.4 Hz, 2H, ArH); [α]24D
+14.8 °, c 2, H2O (lit.224 [α]25D +17.3 °, c 2, H2O).
2-Bromo-(4-methyl)propiophenone (48). Compound 48 was prepared according to a literature
procedure.209 4-Methylpropiophenone (45, 4.0 g, 27.0 mmol) and CH2Cl2 (100 mL) were placed
in a 250 mL flask equipped with a magnetic stir bar. The solution was allowed to stir under an N2
atmosphere and bromine (4.3 g, 27.0 mmol) was added to the flask. (Note: a small amount of
bromine was added to initiate the reaction; the color dissipated as the reaction occured. After the
reaction initiated, the remaining bromine was added over 10 min). A needle was placed in the
septa to allow the HBr gas that formed in the reaction to escape from the flask. After stirring the
solution for 12 h, saturated NaHCO3 was added to bring the pH of the mixture to 9. The aqueous
layer was extracted with CH2Cl2 (3 x 15 mL). The combined organic portion was dried (Na2SO4)
and the solvent was removed under reduced pressure to give a white solid. Recrystallization from
absolute EtOH gave 2.7 g (44%) of 48 as white crystals: mp 75-78 °C (lit.232 mp 76-77 °C); 1H
NMR (CDCl3) δ 1.90 (d, J = 6.6 Hz, 3H, CH3), 2.42 (s, 3H, CH3), 5-25-5.30 (q, 1H, CH), 7.29
(d, J = 8.1 Hz, 2H, ArH), 7.92 (d, J = 8.2 Hz, 2H, ArH).
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2-Bromo-(4-methoxy)propiophenone (49). Compound 49 was prepared using a literature
procedure for a similar compound.209 4-Methoxypropiophenone (46, 4.0 g, 24.4 mmol) and
CH2Cl2 (100 mL) were placed in a 250 mL flask equipped with a magnetic stir bar. The solution
was allowed to stir under an N2 atmosphere and bromine (3.9 g, 24.4 mmol) was added to the
flask. (Note: a small amount of bromine was added to initiate the reaction; the color dissipated as
the reaction occured. After the reaction initiated, the remaining bromine was added over 10 min.)
A needle was placed in the septa to allow the HBr gas that formed in the reaction to escape from
the flask. After stirring the solution for 12 h, saturated NaHCO3 was added to bring the pH of the
mixture to 9. The aqueous layer was extracted with CH2Cl2 (3 x 15 mL). The combined organic
portion was dried (Na2SO4) and the solvent was removed under reduced pressure to give a white
solid. Recrystallization from absolute EtOH gave 4.6 g (78%) of 49 as white crystals: mp 62-64
°C (lit.233 mp 66-69 °C); 1H NMR (CDCl3) δ 1.80 (d, J = 9.6 Hz, 3H, CH3), 3.80 (s, 3H, CH3), 516-5.21 (q, 1H, CH), 6.87 (d, J = 8.7 Hz, 2H, ArH), 7.93 (d, J = 8.8 Hz, 2H, ArH).
2-Bromo-(4-fluoro)propiophenone (50). Compound 50 was prepared using a literature
procedure for a similar compound.209 4-Fluoropropiophenone (47, 4.0 g, 26.3 mmol) and CH2Cl2
(100 mL) were placed in a 250 mL flask equipped with a magnetic stir bar. The solution was
allowed to stir under an N2 atmosphere and bromine (4.2 g, 26.3 mmol) was added to the flask.
(Note: a small amount of bromine was added to initiate the reaction; the color dissipated as the
reaction occured. After the reaction initiated, the remaining bromine was added over 10 min.) A
needle was placed in the septa to allow the HBr gas that formed in the reaction to escape from
the flask. After 12 h, saturated NaHCO3 was added to the stirred solution to pH=9. The aqueous
layer was extracted with CH2Cl2 (3 x 15 mL). The combined organic portion was dried (Na2SO4)
and the solvent was removed under reduced pressure to give white solid. Recrystallization from
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absolute EtOH gave 4.3 g (71%) of 50 as white crystals: mp 33-35 °C (lit.234 mp 33-34 °C); 1H
NMR (CDCl3) δ 1.89 (d, J = 6.6 Hz, 3H, CH3), 3.80 , 5-20-5.25 (q, 1H, CH), 7.13-7.17 (m, 2H,
ArH), 8.04-8.07 (m, 2H, ArH).
1-(4-Methylphenyl)-2-nitropropene (52). Compound 52 was prepared using a literature
procedure for a similar compound.213 p-Methylbenzaldehyde (51, 5.0 g, 41.6 mmol), nitroethane
(3.1 g, 41.6 mmol) and n-butylamine (0.2 mL) were added to absolute EtOH (4 mL). The
solution was heated at reflux for 9 h. On cooling the reaction solution, a heavy, yellow and
crystalline mass was formed. Recrystallization from absolute EtOH gave 2.1 g (29%) of 52 as
yellow crystals: mp 45-48 °C (lit.235 mp 51.5-52.5 °C): 1H NMR (CDCl3) δ 2.41 (s, 3H, CH3),
2.46 (d, J = 0.6 Hz, 3H, CH3), 7.26 (d, J = 8 Hz, 2H, ArH), 7.35 (d, J = 8.1 Hz, 2H, Ar), 8.08 (s,
1H, CH).
N-[1-Methyl-2-(4-methylphenyl)ethyl] methyl carbamate (53). Compound 53 was prepared
using a literature procedure for a similar compound.216 Methyl chloroformate (1.0 g, 10.86
mmol) was added to a solution of 1-(4-methylphenyl)-2-aminopropane (16, 1.3 g, 8.7 mmol) in
CH2Cl2 (30 mL) with a vigorous stirring. Then K2CO3 (6.0 g, 43.6 mmol) in H2O (30 mL) was
added to the reaction mixture and stirring was continued for 1 h. The reaction mixture was
extracted with CH2Cl2 (3 x 10 mL). The organic portion was combined, dried (Na2SO4) and
filtered. The solvent was removed under reduced pressure to give 1.7 g (95%) of crude 53 as an
oil, which was used without further purification for the next step. 1H NMR (CDCl3) δ 1.10 (d, J
= 6.6 Hz, 3H, CH3), 2.32 (s, 3H, CH3), 2.65 (dd, J = 13.5, 7.1 Hz, 1H, CH2), 2.79 (dd, J = 13.3,
5.3 Hz, 1H, CH2), 3.64 (s, 3H, CH3), 3.82-3.98 (m, 1H, CH), 4.51 (br s, 1H, NH), 7.05-7.13 (m,
4H, ArH).
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(R)-N-Methyl-N-[2-chloro-1-methyl-2-oxoethyl]-1,1-dimethylethyl

carbamate

(56).

Compound 56 was prepared using a literature procedure for a similar compound.219 Oxalyl
chloride (1.5 g, 11.7 mmol) was added to a stirred suspension of Boc-N-methyl-D-alanine (55,
1.0 g, 4.9 mmol) in CH2Cl2 (18 mL), cooled to 0 °C (ice-bath) followed by addition of pyridine
(3 drops). The reaction mixture was allowed to warm gradually to room temperature and was
further stirred for 8 h. The solvent and excess oxalyl chloride were removed by rotary
evaporation at 30 °C to afford 1.1 g (100%) of 56 as a colorless oil which was used without
purification for subsequent reaction.
(S)-2-(N-Methyl-N-trifluoroacetyl)aminopropanoic Acid (59). Compound 59 was prepared
using a literature procedure for a similar compound.219 1,1,3,3-Tetramethylguanidine (0.5 g, 5.0
mmol) was added to a suspension of N-methyl-L-alanine (58, 5.0 g, 55 mmol) in MeOH (3 mL).
After 5 min, ethyl trifluoroacetate (0.9 g, 6.0 mmol) was added and the reaction mixture was
allowed to stir for 6 h at room temperature. The solvent was evaporated under reduced pressure
to give an oily residue which was dissolved in H2O (8 mL) and acidified with concentrated HCl
to pH=1. After stirring for 15 min, the mixture was extracted with EtOAc (3 x 20 mL). The
combined organic portion was washed with brine (20 mL) and dried (Na2SO4). The solvent was
evaporated under reduced pressure to give a white solid which was washed with n-hexane (20
mL) and dried to afford 0.9 g (94%) of 59 as an oil; IR (Diamond): 1682 cm-1 (C=O).
(S)-2-(N-Methyl-N-trifluoroacetyl)aminopropanoyl Chloride (60). Compound 60 was
prepared using a literature procedure for a similar compound.219 Oxalyl chloride (1.4 g, 10.7
mmol) was added to a stirred suspension of (S)-2-(N-Methyl-N-trifluoroacetyl)aminopropanoic
acid (59, 0.9 g, 4.5 mmol) in CH2Cl2 (17 mL), at 0 °C (ice-bath); this was followed by addition
of pyridine (1 drop). The reaction mixture was allowed to warm gradually to room temperature
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and was further stirred for 8 h. The solvent and excess oxalyl chloride were removed by rotary
evaporation at 30 °C to afford 1.0 g (100%) of 60 as a colorless oil which was used without
purification for subsequent reactions.
(R)-2-(N-Trifluoroacetyl)aminopropanoic Acid ((R)63). Compound (R)63 was prepared using
a literature procedure for a similar compound.219 1,1,3,3-Tetramethylguanidine (8.6 g, 75 mmol)
was added to a suspension of D-alanine (62, 5.0 g, 55.0 mmol) in MeOH (28 mL). After 5 min,
ethyl trifluoroacetate (9.9 g, 70.0 mmol) was added and the reaction mixture was allowed to stir
for 6 h at room temperature. The solvent was evaporated under reduced pressure to give an oily
residue which was dissolved in H2O (70 mL) and acidified with concentrated HCl to pH=1. After
stirring for 15 min, the mixture was extracted with EtOAc (3 x 20 mL). The combined organic
portion was washed with brine (20 mL) and dried (Na2SO4). The solvent was evaporated under
reduced pressure to give a white solid which was washed with n-hexane (20 mL) and dried to
afford 9.8 g (94%) of (R)63 as a white solid, sufficiently pure for subsequent use: mp 63-65 °C
(lit.236 mp 70-71 °C); IR (Diamond): 1732 cm-1 (C=O).
(S)-2-(N-Trifluoroacetyl)aminopropanoic Acid ((S)63). Compound (S)63 was prepared
according to a literature procedure.219 1,1,3,3-Tetramethylguanidine (8.6 g, 75.0 mmol) was
added to a suspension of L-alanine (5.0 g, 55.0 mmol) in MeOH (28 mL). After 5 min, ethyl
trifluoroacetate (9.9 g, 70.0 mmol) was added and the reaction mixture was allowed to stir for 6 h
at room temperature. The solvent was evaporated under reduced pressure to give an oily residue
which was dissolved in H2O (70 mL) and acidified with concentrated HCl to pH=1. After stirring
for 15 min, the mixture was extracted with EtOAc (3 x 20 mL). The combined organic portion
was washed with brine (20 mL) and dried (Na2SO4). The solvent was evaporated under reduced
pressure to give a white solid which was washed with n-hexane (20 mL) and dried to afford 10.0
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g (96%) of (S)63 as a white solid, sufficiently pure for subsequent use: mp 63-65 °C (lit.219 mp
70-71 °C); IR (Diamond): 1731 cm-1 (C=O).
(R)-2-(N-Trifluoroacetyl)aminopropanoyl Chloride ((R)64). Compound (R)64 was prepared
using a literature procedure for a similar compound.219 Oxalyl chloride (6.4 g, 50.7 mmol) was
added to a stirred suspension of (R)-2-(N-trifluoroacetyl)aminopropanoic acid ((R)63, 4.0 g, 21.6
mmol) in CH2Cl2 (80 mL) at 0 °C (ice-bath), followed by addition of pyridine (3 drops). The
reaction mixture was allowed to warm gradually to room temperature and was further stirred for
8 h. The solvent and excess oxalyl chloride were removed by rotary evaporation at 30 °C
afforded 4.4 g (100%) of (R)64 as a colorless oil which was used without purification for
subsequent reactions.
(S)-2-(N-Trifluoroacetyl)aminopropanoyl Chloride ((S)64). Compound (S)64 was prepared
according to a literature procedure.219 Oxalyl chloride (4.8 g, 38.0 mmol) was added to a stirred
suspension of (S)-2-(N-trifluoroacetyl)aminopropanoic acid ((S)63, 3.0 g, 16.2 mmol) in CH2Cl2
(60 mL) at 0 °C (ice-bath), followed by addition of pyridine (3 drops). The reaction mixture was
allowed to warm gradually to room temperature and was further stirred for 8 h. The solvent and
excess oxalyl chloride were removed by rotary evaporation at 30 °C to afford 3.3 g (100%) of
(S)64 as a colorless oil which was used without purification for subsequent reactions.
(R)-N-[2-(4-Methylphenyl)-1-methyl-2-oxoethyl]-2,2,2-trifluoroacetamide

((R)65).

Compound (R)65 was prepared using a literature procedure for a similar compound.219 Toluene
(23.0 g, 251.0 mmol) and AlCl3 (5.8 g, 43.2 mmol) were added to (R)-2-(Ntrifluoroacetyl)aminopropanoyl chloride ((R)64, 4.4 g, 21.6 mmol) at room temperature. The
reaction mixture was allowed to stir for 18 h and then cooled in an ice-bath and slowly quenched
with 1N HCl (80 mL). The aqueous layer was extracted with CH2Cl2 (3 x 20 mL) and the organic
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portions were combined and dried (Na2SO4). The solvent was evaporated under reduced pressure
to give the crude product as an orange oil which was purified by column chromatography (silica
gel; hexane/EtOAc; 9.7:0.3) to give 0.9 g (22%) of (R)65 as a white solid: mp 77-78 °C; 1HNMR (CDCl3) δ 1.52 (d, J = 7.1 Hz, 3H, CH3), 2.45 (s, 3H, CH3), 5.44-5.53 (m, 1H, CH), 7.33
(d, J = 8.0 Hz, 2H, ArH), 7.61 (s, 1H, NH), 7.88 (d, J = 8.3 Hz, 2H, ArH).
(S)-N-[2-(4-Methylphenyl)-1-methyl-2-oxoethyl]-2,2,2-trifluoroacetamide

((S)65).

Compound (S)65 was prepared according to a literature procedure.219 Toluene (17.3 g, 188.0
mmol) and AlCl3 (4.3 g, 32.4 mmol) were added to (S)-2-(N-trifluoroacetyl)aminopropanoyl
chloride ((S)64, 3.3 g, 16.2 mmol) at room temperature. The reaction mixture was allowed to stir
for 18 h and, then cooled in an ice-bath and slowly quenched with 1N HCl (60 mL). The aqueous
layer was extracted with CH2Cl2 (3 x 20 mL) and the organic portions were combined and dried
(Na2SO4). The solvent was evaporated under reduced pressure to give the crude product as an
orange oil which was purified by column chromatography (silica gel; hexane/EtOAc; 9.7:0.3) to
give 0.7 g (17%) of (S)65 as a white solid: mp 77-78 °C (lit.219 mp 77-78 °C); 1H-NMR (CDCl3)
δ 1.52 (d, J = 7.2 Hz, 3H, CH3), 2.45 (s, 3H, CH3), 5.46-5.53 (m, 1H, CH), 7.33 (d, J = 8.0 Hz,
2H, ArH), 7.61 (s, 1H, NH), 7.88 (d, J = 8.3 Hz, 2H, ArH).
N-Methyl-N-[2-(4-methylphenyl)-1-methyl-2-oxoethyl]-2,2,2-trifluoroacetamide

(66).

Compound 66 was prepared using a literature procedure for a similar compound.220 (S)-N-[2-(4Methylphenyl)-1-methyl-2-oxoethyl]-2,2,2-trifluoroacetamide (65, 1.4 g, 5.4 mmol) was
dissolved in dry acetone (30 mL), and to that anhydrous K2CO3 (1.5 g, 10.9 mmol) and CH3I (3.1
g, 21.8 mmol) were added. The reaction mixture was heated at reflux for 48 h. The solvent was
removed under reduced pressure and the residue was dissolved in H2O (3 mL). The aqueous
layer was extracted with Et2O (3 x 20 mL) and the organic portions were combined and dried
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(Na2SO4). The solvent was evaporated under reduced pressure to give the crude product as an oil
which was purified by column chromatography (silica gel; hexane/EtOAc; 9.9:0.1) to give 1.4 g
(94%) of 66 as a colorless oil; 1H-NMR (CDCl3) δ 1.44 (d, J = 7 Hz, 3H, CH3), 2.41 (s, 3H,
CH3), 2.96 (s, 3H, CH3), 5.97-6.02 (m, 1H, CH), 7.27 (d, J = 7 Hz, 2H, ArH, 7.83 (d, J = 8.3 Hz,
2H, ArH).
(S)-N-(2-Phenyl-1-methylethyl)acetamide (69). Compound 69 was prepared according to a
literature procedure.222 Acetic anhydride (2.1 mL, 22.2 mmol) was added to a stirred suspension
of Na2CO3 (7.8 g, 73.9 mmol) and S(+)-amphetamine hemisulfate (S(+)1, 3.4 g, 9.3 mmol) in
H2O (22 mL) at 0 °C (ice-bath). The suspension was allowed to stir for 5 h at room temperature,
and then extracted with CHCl3 (3 x 20 mL); the combined organic portion was washed with H2O
(3 x 10 mL) and dried (Na2SO4). The solvent was evaporated under reduced pressure to give a
white solid. Recrystallization from i-PrOH gave 2.5 g (76%) of 69 as white crystals: mp 121-123
°C (lit.222 mp 121-124 °C); 1H NMR (CDCl3) δ 1.09 (d, J = 6.7 Hz, 3H, CH3), 1.92 (s, 3H, CH3),
2.71 (dd, J = 13.5, 7.1 Hz, 1H, CH2), 2.82 (dd, J = 13.5, 5.7 Hz, 1H, CH2), 4.22-4.29 (m, 1H,
CH), 5.22 (br s, 1H, NH), 7.16 (d, J = 6.8 Hz, 2H, ArH), 7.17-7.29 (m, 3H, ArH).
1-Phenyl-2-nitropropene (71). Compound 71 was prepared according to a literature
procedure.213 Benzaldehyde (70, 2.0 g, 18.8 mmol), nitroethane (1.4 g, 18.8 mmol) and nbutylamine (0.1 mL) were added to absolute EtOH (1.9 mL). The solution was heated at reflux
for 9 h. On cooling the reaction solution, a heavy, yellow and crystalline mass was formed.
Recrystallization from absolute EtOH gave 1.1 g (36%) of 71 as yellow crystals: mp 61-62 °C
(lit.113 mp 65 °C); 1H NMR (CDCl3) δ 2.27 (d, J = 1.0 Hz, 3H, CH3), 7.23-7.29 (m, 5H, ArH),
7.90 (s, 1H, CH).
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(R)-N-[2-(3,4-Dichlorophenyl)-1-methyl-2-oxoethyl]-2,2,2-trifluoroacetamide

(72).

Compound 72 was prepared using a literature procedure for a similar compound.219 3,4Dichlorobenzene (19.1 g, 129.6 mmol) and AlCl3 (4.3 g, 32.4 mmol) were added to (R)-2-(Ntrifluoroacetyl)aminopropanoyl chloride ((R)64, 3.3 g, 16.2 mmol) at room temperature. The
reaction mixture was allowed to stir for 18 h and then cooled in an ice-bath and slowly quenched
with 1N HCl (80 mL). The aqueous layer was extracted with CH2Cl2 (3 x 20 mL) and the organic
portions were combined and dried (Na2SO4). The solvent was evaporated under reduced pressure
to give the crude product as an oil which upon standing for 2 days gave 0.01 g (0.2%) of 72 as a
white solid; 1H-NMR (CDCl3) δ 1.52 (d, 3H, CH3), 5.30 (s, 1H, NH), 5.42-5.49 (q, 1H, CH),
7.79 (d, J = 2 Hz, 1H, ArH), 7.81 (d, J = 2 Hz, 1H, ArH), 8.07 (s, 1H, ArH). Anal. Calcd
(C11H8Cl2F3NO2·0.25H2O) C, 41.47; H, 2.69; N, 4.40. Found: C, 41.06; H, 2.36; N, 4.27.
1-(3,4-Dichlorophenyl)-2-nitropropene (74). Compound 74 was prepared using a literature
procedure for a similar compound.213 3,4-Dichlorobenzaldehyde (73, 5.0 g, 28.6 mmol),
nitroethane (2.1 g, 28.6 mmol) and n-butylamine (0.1 mL) were added to absolute EtOH (3 mL).
The solution was heated at reflux for 9 h. On cooling the reaction solution, a heavy, yellow and
crystalline mass was formed. Recrystallization from absolute EtOH gave 4.0 g (61%) of 74 as
yellow crystals: mp 70-72 °C (lit.237 mp 81 °C): 1H NMR (CDCl3) δ 0.07 (s, H, CH), 2.43 (d, 3H,
CH3), 7.96 (s, 1H, ArH), 7.51-7.54 (m, 1H, ArH), 7.24-7.27 (m, 1H, ArH).

B.

ELECTROPHYSIOLOGY:
Xenopus laevis oocytes were harvested and prepared using Xenopus laevis females.228,229

Oocytes from stage V-VI were selected for cRNA injection within 24 hours of isolation. The
pOTV vector was used to transcribe cRNA using mMessage Machine T7 kit (Ambion Inc.,
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Austin, TX). Each oocyte was injected with 50 nL of 1 μg/μL hDAT cRNA and was incubated in
Ringers solution supplemented with Na+ pyruvate (550 μg/mL), tetracycline (50 μg/mL), and 5%
dialyzed horse serum. In all assays, oocytes were held at -60 mV in a two-electrode voltage
system and maintained in a bath containing standard recording solution (120 mM NaCl, 5.4 mM
K gluconate, 1.2 mM Ca gluconate, 15 mL of 0.5 M HEPES). In all assays measuring EC50,
compound’s concentrations were varied depending on the response observed. Each concentration
point was confirmed by at least three different oocytes measurements. In the recording,
dopamine was perfused for 30 sec followed by the drug application which was applied for 1 min.
The drug response was always represented as a percent of dopamine response as a normalization
measure. Using Clampfit, raw traces were filtered and values for the dopamine and the drug
induced responses were obtained for an analysis in Origin 8, y=Vmax*x^n/(k^n+x^n). (Note:
Electrophysiological studies were done by Krasnodara Cameron, a graduate student in Dr. De
Felice Laboratory)
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